Anti-claudin bispecific antibodies
By developing bispecific antibodies targeting CLDN18.2 and CD3, the problem of difficult to effectively target and clear CLDN18.2 expressing cells in the prior art was solved, and effective targeting and clearing of tumor cells was achieved, showing good results. anti-tumor effects and safety.
Patent Information
- Application Number
- CN202410533120.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to effectively target and clear tumor cells expressing CLDN18.2, and there is a lack of bispecific antibodies against CLDN18.2 and c-Met, which affects the anti-tumor treatment effect.
Bispecific antibodies targeting CLDN18.2 and CD3, containing specific amino acid sequence combinations, were developed to specifically bind CLDN18.2 and CD3, inducing cytotoxic effects against target cells.
Effective targeting and clearing of tumor cells expressing CLDN18.2 was achieved, and good anti-tumor effects and safety were demonstrated.
Smart Images

Figure CN118894944A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure belongs to the field of biomedicine, and relates to bispecific antibodies, and in particular to anti-claudin bispecific antibodies. The present disclosure also relates to a preparation method and use of the bispecific antibodies. Background Art
[0002] Tight junction protein 18 (CLDN18 or Claudin 18) belongs to the family of tight junction proteins, participates in the formation of tight junctions between cells, controls the flow of molecules between cells, and plays an important role in maintaining cell polarity, permeability and intercellular signal transduction. CLDN18 is a four-transmembrane protein with both the N-terminus and the C-terminus in the cell and two loop regions formed outside the cell. Due to the selective splicing of RNA, there are two different subtypes in tissues: tight junction protein 18.1 (CLDN18.1, for example, the Uniprot accession number of human CLDN18.1 is P56856-1) and tight junction protein 18.2 (CLDN18.2, for example, the Uniprot accession number of human CLDN18.2 is P56856-2).
[0003] The protein sequences of CLDN18.1 (Claudin 18.1) and CLDN18.2 (Claudin 18.2) are highly similar, but their expression distributions are different. CLDN18.1 is selectively expressed in normal lung tissue, while the expression of CLDN18.2 in normal tissue is very limited and is only specifically expressed in differentiated epithelial cells of the gastric mucosa. However, studies have found that CLDN18.2 is highly expressed in 70% of primary gastric cancers and their metastatic lesions. In addition, CLDN18.2 has been found to be frequently ectopically activated in a variety of malignant tumors, including pancreatic cancer, esophageal cancer, lung cancer, breast cancer, ovarian cancer, and ear, nose and throat tumors (Niimi et al., (2001) Mol Cell Biol 21(21): 7380-7390; Sahin, U. et al., (2008) Clin Cancer Res. 14, 7624-34; Tanaka et al., (2011) J Histochem Cytochem 59(10): 942-952; Micke et al., (2014) Int J Cancer 135(9): 2206-2214; Shimobaba et al., (2016) Biochim Biophys Acta 1863(6Pt A): 1170-1178; Sing h et al., (2017) J Hema tol Oncol 10(1): 105; Tokumitsu et al., (2017) Cytopathology 28(2): 116-121).
[0004] Bispecific antibodies targeting CLDN18.2 and the T cell CD3 receptor can redirect CD3 T cells to tumor cells expressing CLDN18.2 to induce cytotoxicity against target cells. Therefore, there is a need to develop bispecific antibodies targeting CLDN18.2 and c-Met. Summary of the invention
[0005] Brief description of the invention
[0006] The present disclosure provides bispecific antibodies targeting CLDN18.2 and CD3, and also provides related nucleic acids, vectors, cells, pharmaceutical compositions, preparation methods and uses capable of encoding the provided antibodies.
[0007] In one aspect, the present disclosure provides a bispecific antibody comprising a first antigen binding moiety that binds CLDN18.2 and a second antigen binding moiety that binds CD3, wherein the first antigen binding moiety comprises:
[0008] (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6;
[0009] (2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6;
[0010] (3) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:60, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6;
[0011] (4) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:61, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6;
[0012] (5) a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14;
[0013] (6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
[0014] (7) a HCDR1 comprising the amino acid sequence of SEQ ID NO:25, a HCDR2 comprising the amino acid sequence of SEQ ID NO:26, a HCDR3 comprising the amino acid sequence of SEQ ID NO:27, a LCDR1 comprising the amino acid sequence of SEQ ID NO:28, a LCDR2 comprising the amino acid sequence of SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:30; or
[0015] (8) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:38.
[0016] In one aspect, the present disclosure also provides a bispecific antibody comprising a first antigen binding moiety that binds CLDN18.2 and a second antigen binding moiety that binds CD3, wherein the first antigen binding moiety comprises:
[0017] (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:8;
[0018] (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 15, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 16;
[0019] (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:24;
[0020] (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:32;
[0021] (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40;
[0022] (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:62, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0023] (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0024] (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0025] (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0026] (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:68;
[0027] (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:67, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:68;
[0028] (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:69, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:72;
[0029] (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence of SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence of SEQ ID NO:72; or
[0030] (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region whose amino acid sequence is shown in SEQ ID NO:71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region whose amino acid sequence is shown in SEQ ID NO:72.
[0031] In some embodiments, the first antigen binding moiety comprises:
[0032] (1) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8;
[0033] (2) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:15, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:16;
[0034] (3) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24;
[0035] (4) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:32;
[0036] (5) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40;
[0037] (6) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:62, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0038] (7) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0039] (8) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0040] (9) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0041] (10) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0042] (11) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0043] (12) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72;
[0044] (13) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72; or
[0045] (14) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:71, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:72.
[0046] In some embodiments, the second antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:98, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:99, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:100, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:101, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:102, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:103.
[0047] In some embodiments, the second antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:104, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:105.
[0048] In some specific embodiments, the bispecific antibody comprises a first antigen-binding portion that binds to CLDN18.2 and a second antigen-binding portion that binds to CD3; wherein the first antigen-binding portion comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:2, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6; the second antigen-binding portion comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:98, a HCDR2 comprising the amino acid sequence of SEQ ID NO:99, a HCDR3 comprising the amino acid sequence of SEQ ID NO:100, a LCDR1 comprising the amino acid sequence of SEQ ID NO:101, a LCDR2 comprising the amino acid sequence of SEQ ID NO:102, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:103.
[0049] In other specific embodiments, the bispecific antibody comprises a first antigen-binding portion that binds to CLDN18.2 and a second antigen-binding portion that binds to CD3; wherein the first antigen-binding portion comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14; the second antigen-binding portion comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:98, a HCDR2 comprising the amino acid sequence of SEQ ID NO:99, a HCDR3 comprising the amino acid sequence of SEQ ID NO:100, a LCDR1 comprising the amino acid sequence of SEQ ID NO:101, a LCDR2 comprising the amino acid sequence of SEQ ID NO:102, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:103.
[0050] In some specific embodiments, the bispecific antibody comprises a first antigen binding portion that binds to CLDN18.2 and a second antigen binding portion that binds to CD3, wherein the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 63 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 68; the second antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 104 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 105.
[0051] In other specific embodiments, the bispecific antibody comprises a first antigen binding portion that binds to CLDN18.2 and a second antigen binding portion that binds to CD3, wherein the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 69 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 72; the second antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 104 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 105.
[0052] In some embodiments, the bispecific antibodies of the present disclosure comprise an Fc domain composed of two Fc polypeptides.
[0053] In some embodiments, the first antigen binding moiety and the second antigen binding moiety are each independently Fab, scFv, scFab (single-chain Fab) or other structures. In some embodiments, the first antigen binding moiety is Fab and the second antigen binding moiety is scFv.
[0054] In some embodiments, the bispecific antibody disclosed herein has a first antigen binding moiety of Fab and a second antigen binding moiety of scFv, wherein the first antigen binding moiety is fused at the C-terminus of its Fab heavy chain or Fab light chain to the N-terminus of one of the Fc polypeptides of the Fc domain, and the second antigen binding moiety is fused at its C-terminus to the N-terminus of another Fc polypeptide of the Fc domain. In a further more specific embodiment, the bispecific antibody is composed of three polypeptide chains, wherein the first polypeptide chain contains the Fab light chain of the first antigen binding moiety, the second polypeptide chain contains the Fab heavy chain of the first antigen binding moiety and one of the Fc polypeptides of the Fc domain, and the third polypeptide chain contains the second antigen binding moiety and another Fc polypeptide of the Fc domain.
[0055] In some embodiments, the bispecific antibody is bivalent.
[0056] In another aspect, the present disclosure provides an antibody, or antigen-binding portion thereof, that binds to CLDN18.2, comprising:
[0057] (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6;
[0058] (2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6;
[0059] (3) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:60, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6;
[0060] (4) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:61, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6;
[0061] (5) a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14;
[0062] (6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
[0063] (7) a HCDR1 comprising the amino acid sequence of SEQ ID NO:25, a HCDR2 comprising the amino acid sequence of SEQ ID NO:26, a HCDR3 comprising the amino acid sequence of SEQ ID NO:27, a LCDR1 comprising the amino acid sequence of SEQ ID NO:28, a LCDR2 comprising the amino acid sequence of SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:30; or
[0064] (8) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:38.
[0065] In one aspect, the present disclosure also provides an antibody or antigen-binding portion thereof that binds to CLDN18.2, comprising:
[0066] (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:8;
[0067] (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 15, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 16;
[0068] (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:24;
[0069] (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:32;
[0070] (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40;
[0071] (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:62, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0072] (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0073] (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0074] (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0075] (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:68;
[0076] (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:67, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:68;
[0077] (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:69, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:72;
[0078] (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence of SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence of SEQ ID NO:72; or
[0079] (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region whose amino acid sequence is shown in SEQ ID NO:71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region whose amino acid sequence is shown in SEQ ID NO:72.
[0080] In one aspect, the disclosure provides an isolated nucleic acid comprising a nucleotide sequence encoding a bispecific antibody or antibody or antigen-binding portion thereof as described in the disclosure.
[0081] In one aspect, the present disclosure provides a vector comprising a nucleic acid described in the present disclosure.
[0082] In one aspect, the present disclosure provides a host cell comprising the nucleic acid described in the present disclosure, or the vector described in the present disclosure.
[0083] In one aspect, the present disclosure provides an antibody drug conjugate comprising an antibody of the present disclosure that binds CLDN18.2, or an antigen-binding portion thereof.
[0084] In one aspect, the present disclosure provides an anti-CLDN18.2 chimeric antigen receptor comprising an antibody of the present disclosure that binds to CLDN18.2.
[0085] In one aspect, the present disclosure provides engineered immune effector cells comprising the chimeric antigen receptor of the present disclosure.
[0086] On the other hand, the present disclosure provides a method for preparing the bispecific antibody, or antibody or antigen-binding portion thereof described in the present disclosure, which comprises culturing the host cell to express the bispecific antibody, or antibody or antigen-binding portion thereof, and separating and purifying the bispecific antibody, or antibody or antigen-binding portion thereof in the system. On the other hand, the present disclosure provides a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, the antibody-drug conjugate, the engineered immune effector cell or the bispecific antibody, and a pharmaceutically acceptable excipient.
[0087] On the other hand, the present disclosure provides use of the antibody or antigen-binding portion thereof, the antibody-drug conjugate, the engineered immune effector cell, the bispecific antibody or the pharmaceutical composition in the preparation of a medicament for treating a disease expressing CLDN18.2.
[0088] In another aspect, the present disclosure provides a method for treating a disease expressing CLDN18.2, comprising administering the antibody or antigen-binding portion thereof, the antibody-drug conjugate, the engineered immune effector cell, the bispecific antibody or the pharmaceutical composition to a subject in need thereof.
[0089] In another aspect, the present disclosure provides a method for treating a disease expressing CLDN18.2, comprising administering a therapeutically effective amount of the antibody or antigen-binding portion thereof, the antibody-drug conjugate, the engineered immune effector cell, the bispecific antibody or the pharmaceutical composition to a subject in need thereof.
[0090] The bispecific antibodies targeting CLDN18.2 and CD3 provided in the present disclosure exhibit good anti-tumor effects and / or safety. DETAILED DESCRIPTION OF THE INVENTION
[0092] I. Definition and Explanation
[0093] Unless otherwise indicated, the following terms used in this disclosure have the following meanings. A particular term should not be considered as indefinite or unclear in the absence of a special definition, but should be understood according to the common meaning in the art. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.
[0094] The term "antibody" is used in the broadest sense to cover natural antibodies and artificial antibodies of various structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies and multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies), and various antibody structures of single-chain antibodies, as long as they show the desired antigen-binding activity.
[0095] The term "multi-specific" means that the antibody can specifically bind to a variety of different antigenic determinants, for example, it can specifically bind to two (ie, "bispecific") or more different antigenic determinants. Antigenic determinants herein are synonymous with antigenic epitopes. Typically, bispecific antibodies contain two antigen binding sites, each of which is specific for a different antigenic determinant. Different antigenic determinants can be expressed on the same or different cells. Different antigenic determinants can be different due to different antigen types (for example, binding antigens CLDN18.2 and CD3), or they can exist on the same antigen. An antigenic determinant is a special chemical group with a certain composition and structure on the surface of an antigenic substance molecule or other parts, which can specifically bind to its corresponding antibody or sensitized lymphocyte. An example of an antigenic determinant is that CLDN18.2, as an antigenic substance, has a variety of antigenic determinants with determined or undetermined structures. A specific bispecific antibody can, for example, bind to CLDN18.2 and CD3.
[0096] The term "antigen binding moiety" refers to a polypeptide molecule that specifically binds to an antigenic determinant. Specific antigen binding moieties may be, for example, Fab, scFv or scFab.
[0097] The terms "first", "second" or "third" used in the present disclosure with respect to antigen-binding moieties, antigens, Fc polypeptides, peptide linkers, polypeptide chains, etc., are used for the convenience of distinguishing when there is more than one of each type of moiety. Unless explicitly stated, the use of these terms is not intended to confer a specific order or orientation.
[0098] The term "fusion" means that the components (e.g., antigen binding moiety, Fc polypeptide, etc.) are connected by peptide bonds directly or via one or more peptide linkers. For example, some peptide linkers consist of 1 to 50 amino acids connected by peptide bonds, wherein the amino acids can be selected from 20 naturally occurring amino acids; in a more preferred embodiment, 1 to 50 amino acids are selected from glycine, alanine, proline, serine, asparagine, glutamine and lysine.
[0099] The term "variable domain" or "variable region" refers to the domain of an antibody that is involved in binding the antibody to an antigen. For example, a natural four-chain antibody (e.g., derived from humans, mice, etc.) has a heavy chain variable region (also referred to as a heavy chain variable domain, VH or VH domain) and a light chain variable region (also referred to as a light chain variable domain, VL or VL domain). In most cases, each variable domain of a natural antibody is essentially composed of four "framework regions (FR)" and three "complementarity determining regions (CDR)". The four framework regions are respectively referred to as framework region 1 (or FR1), framework region 2 (or FR2), framework region 3 (or FR3), and framework region 4 (or FR4); the framework region is separated by three complementary determining regions, which are respectively referred to as complementary determining region 1 (or CDR1), complementary determining region 2 (or CDR2), and complementary determining region 3 (or CDR3) in the art and hereinafter. Therefore, the general structure of the variable domain can be expressed as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The variable domain confers specificity to the antibody for the antigen by providing the antigen binding site.
[0100] The term "complementarity determining region" (CDR), also known as "hypervariable region" (HVR). A natural four-chain antibody usually contains six CDRs, three in the heavy chain variable region, namely heavy chain CDR1 (HCDR1), heavy chain CDR2 (HCDR2) and heavy chain CDR3 (HCDR3); three in the light chain variable region, namely light chain CDR1 (LCDR1), light chain CDR2 (LCDR2) and light chain CDR3 (LCDR3).
[0101] There are many methods to divide and define CDR at present. Among them, Kabat definition divides CDR based on sequence variability, and is the most commonly used (Elvin A.Kabat, et al, Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, Md. (1991)); and Chothia definition is based on the position of structural loop (Cyrus Chothia, et al, Canonical Structures for the Hypervariable Regions of Immunoglobulins, J.Mol.Biol.196:901-917 (1987)). AbM definition is a compromise between Kabat definition and Chothia definition, and is used by AbM antibody modeling software of Oxford Molecular. The basis of "contact" definition CDR is the analysis of available complex crystal structure. In addition, there is CCG definition. However, it should be noted that the boundaries of the CDRs of the same antibody variable region obtained by different division definitions may be different, that is, the CDR sequences of the same antibody variable region divided and defined by different methods may be different. Therefore, when it comes to defining antibodies by specific CDR sequences, the scope of the antibodies also covers antibodies defined by CDR sequences of other arbitrary definitions (e.g., a combination of one or more of the definitions of Kabat, IMGT, Chothia, Contact, AbM, CCG, etc.).
[0102] The term "Fab" refers to a protein consisting of the VH and CH1 of the heavy chain and the VL and CL domains of the light chain of an immunoglobulin. Fab herein means a Fab molecule in its natural form or modified, i.e., comprising a Fab heavy chain (VH-CH1, N to C-terminal direction) consisting of a heavy chain variable region VH and a constant region CH1, and a Fab light chain (VL-CL, N to C-terminal direction) consisting of a light chain variable region VL and a constant region CL. The modified Fab may, for example, be a Fab in which amino acid substitutions are introduced into the CH1 / CL domain or / and the VH / VL domain. In a specific example, the modified Fab may be a Fab in which amino acid substitutions are introduced into the CL domain.
[0103] The term "scFv" includes the VH and VL domains of an immunoglobulin, wherein these domains are present in a single polypeptide chain. In some embodiments, the scFv further comprises a peptide linker between the VH and VL domains that enables the scFv to form a structure required for antigen binding. In a specific example, the scFv is arranged in the following order from the N-terminus to the C-terminus: VH-linker-VL.
[0104] The term "Fc domain", "Fc" or "Fc domain" is used herein to define the C-terminal region of an immunoglobulin heavy chain that includes at least a portion of a constant region. The term includes native sequence Fc and variant Fc. The C-terminal lysine (Lys447) of Fc may be present or absent. Unless otherwise indicated, the numbering of amino acid residues in Fc or the constant region is according to the EU numbering system, also known as the EU index, described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242. One of the "Fc polypeptides" of the Fc domain used herein refers to one of the two polypeptides that form a dimeric Fc domain. For example, the Fc polypeptide of the IgG Fc domain comprises IgG CH2 and IgG CH3.
[0105] The term "treat" means administering a compound (e.g., a monospecific antibody, a bispecific antibody) or a pharmaceutical composition of the present disclosure to prevent, ameliorate or eliminate a disease or one or more symptoms associated with the disease, and includes but is not limited to: (i) preventing a disease or disease state from occurring in a mammal, particularly when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state; (ii) inhibiting a disease or disease state, i.e., curbing its development; (iii) relieving a disease or disease state, i.e., causing the disease or disease state to regress; and (iv) reducing any direct or indirect pathological consequences of a disease or disease state.
[0106] The term "therapeutically effective amount" means an amount of a compound of the present disclosure that (i) treats or prevents a specific disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a specific disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition, or disorder described herein. The amount of a monospecific antibody, bispecific antibody, antibody drug conjugate, engineered immune effector cell, or pharmaceutical composition of the present disclosure that constitutes a "therapeutically effective amount" may vary depending on factors such as the compound or pharmaceutical composition and its ability to elicit a desired response in an individual, the disease state and its severity, the mode of administration, and the age, sex, and weight of the mammal to be treated. A therapeutically effective amount may also be routinely determined by a person skilled in the art based on their own knowledge and the present disclosure.
[0107] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0108] The term "excipient" refers to any ingredient other than an active ingredient (eg, an antibody of the present disclosure). The choice of excipient will largely depend on factors such as the particular mode of administration, the efficacy of the excipient on solubility and stability, and the nature of the dosage form.
[0109] The term "isolated" refers to a compound of interest, such as an antibody or antigen-binding fragment thereof, or a nucleic acid, that has been separated from its natural environment.
[0110] The term "X n " is equivalent to "Xaa" and refers to an unspecified amino acid, and its scope is specified by the subsequent definition in the relevant expression.
[0111] As used herein, the term “EC 50 ", or half maximal effective concentration, refers to the concentration of the antibody when the induced response is 50% of the maximum response, that is, halfway between the maximum response and the baseline. EC 50 Measurement may be performed by ELISA or FACS analysis or any other method known in the art.
[0112] “K D ” refers to the equilibrium dissociation constant, which is obtained from the dissociation rate constant (k d ) than the binding rate constant (k a )(i.e., k d / k a) and expressed as molar concentration (M). D The K value can be determined using methods well established in the art. D A preferred method is by using surface plasmon resonance (SPR) technology, preferably using a biosensor system such as a Biacore surface plasmon resonance system analysis.
[0113] The term "identity" is also known as consistency. The "percentage (%) identity" of an amino acid sequence refers to the percentage of amino acid residues in the sequence to be compared that are identical to the amino acid residues in the specific amino acid sequence shown in this article, after comparing the sequence to be compared with the specific amino acid sequence shown in this article and introducing spaces if necessary to achieve the maximum sequence identity percentage, and not considering any conservative substitutions as part of the sequence identity. The amino acid sequence alignment of identity can be carried out in a variety of ways within the scope of the art, such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for comparing sequences, including any algorithm required to obtain the maximum alignment in the full length of the comparison sequence.
[0114] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cattle, chickens, amphibians, reptiles, etc. Preferably, the subject according to the present disclosure is a human. Unless otherwise indicated, the terms "patient" or "subject" can be used interchangeably. "Subjects in need" include those subjects who already have a disease or condition, subjects who are at risk of developing a disease or condition, and subjects who may have a disease or condition and whose purpose is to prevent, delay or attenuate the disease or condition.
[0115] As used herein, "about" means within the acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within 1 or more than 1 standard deviation as practiced in the art. Alternatively, "about" may mean a range of up to ±5%, such as fluctuations within ±2%, within ±1%, or within ±0.5% of a given specific numerical range. When a specific value is given in the scope of the present disclosure, unless otherwise indicated, the meaning of "about" should be considered to be within the acceptable error range for that specific value. In this document, unless otherwise indicated, the values of step parameters or conditions are modified by "about" by default.
[0116] The terms "comprise," "comprises," or "comprising" and their equivalents (for example, contain, contains, containing, include, includes, and including) should be understood as "including but not limited to," meaning that in addition to the listed elements, components, and steps, other unspecified elements, components, and steps may also be included.
[0117] Herein, singular terms include plural referents and vice versa unless the context clearly dictates otherwise.
[0118] II. Monospecific Antibodies or Antigen-Binding Portions thereof
[0119] The present disclosure provides a monospecific antibody or an antigen-binding portion thereof that binds to CLDN18.2, comprising: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, 9, 17, 25 or 33, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 59, 10, 18, 26 or 34, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 3, 11, 19, 27 or 35, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 4, 12, 20, 28 or 36, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, 13, 21, 29 or 37, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 6, 14, 22, 30 or 38.
[0120] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; wherein X 1 Select from N or Q, X 2 is selected from S or T. In some specific embodiments, the X 1 is N, and X 2 is S. In some specific embodiments, the X 1 is N, and X 2 is T. In some specific embodiments, the X 1 is Q, and X 2 For S.
[0121] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0122] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:60, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0123] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0124] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14.
[0125] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:17, a HCDR2 comprising the amino acid sequence of SEQ ID NO:18, a HCDR3 comprising the amino acid sequence of SEQ ID NO:19, a LCDR1 comprising the amino acid sequence of SEQ ID NO:20, a LCDR2 comprising the amino acid sequence of SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:22.
[0126] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:25, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:26, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:27, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:28, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:30.
[0127] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:38.
[0128] The present disclosure also provides a monospecific antibody or an antigen-binding portion thereof that binds to CLDN18.2, comprising: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in the amino acid sequence of SEQ ID NO: 7, 15, 23, 31, 39, 67 or 71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in the amino acid sequence of SEQ ID NO: 8, 16, 24, 32, 40, 68 or 72.
[0129] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:8.
[0130] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:15, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:16.
[0131] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:24.
[0132] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:32.
[0133] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:40.
[0134] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:62, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0135] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0136] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0137] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0138] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0139] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 67, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 68; wherein X 3 Selected from I or L, X 4 Select from N or Q, X 5 Select from S or T, X 6 Select from V or L, X 7 Select from T or S, X 8 Select from V or K, X 9 Select from T or N.
[0140] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:69, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:72.
[0141] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:72.
[0142] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 71, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 72; wherein X 10 Selected from V or I, X 11 Select from A or T, X 12 Select from Q or K, X 13 Select from T or R, X 14 Select from S or N.
[0143] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 7, 15, 23, 31, 39, 62, 63, 64, 65, 66, 67, 69, 70 or 71, and an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: The amino acid sequence shown in NO:8, 16, 24, 32, 40, 68 or 72 has a light chain variable region that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.
[0144] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0145] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 15, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 16. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0146] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.
[0147] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:31, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:32. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:25, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:26, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:27, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:28, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:30.
[0148] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:38.
[0149] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:62, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0150] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0151] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0152] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:60, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0153] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0154] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 67, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 68; wherein X 3 Selected from I or L, X 4 Select from N or Q, X 5 Select from S or T, X 6 Select from V or L, X 7 Select from T or S, X 8 Select from V or K, X 9 is selected from T or N. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 further comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; wherein X 1 Select from N or Q, X 2 Select from S or T.
[0155] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0156] In some embodiments, the monospecific antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprises a heavy chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain variable region whose amino acid sequence is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0157] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 71, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 72; wherein X 10 Selected from V or I, X 11 Select from A or T, X 12 Select from Q or K, X 13 Select from T or R, X 14 is selected from S or N. Further, in some such embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 further comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14.
[0158] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:7, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:8.
[0159] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:15, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:16.
[0160] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:23, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:24.
[0161] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:32.
[0162] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:40.
[0163] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:62, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0164] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0165] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0166] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0167] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0168] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:67, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0169] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0170] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0171] In some embodiments, the monospecific antibody or antigen-binding portion thereof that binds CLDN18.2 comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:71, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0172] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:7, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:8.
[0173] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:15, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:16.
[0174] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:23, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:24.
[0175] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:32.
[0176] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:40.
[0177] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:62, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:68.
[0178] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:68.
[0179] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:68.
[0180] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:68.
[0181] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:68.
[0182] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:67, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:68.
[0183] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:69, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:72.
[0184] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:72.
[0185] In some specific embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 comprises a heavy chain variable region with the amino acid sequence shown in SEQ ID NO:71, and a light chain variable region with the amino acid sequence shown in SEQ ID NO:72.
[0186] In the present disclosure, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 is murine, chimeric or humanized. Humanization can reduce immunogenicity. Therefore, in some embodiments, the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 is humanized.
[0187] In some embodiments, the monospecific antibodies binding to CLDN18.2 of the present disclosure may also include a constant region of an immunoglobulin, or a fragment, analog, variant or derivative of the constant region. In some embodiments, the constant region includes a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region is from a human immunoglobulin heavy chain, such as IgG1, IgG2, IgG3 and IgG4 or other classes of immunoglobulin heavy chains. In some embodiments, the light chain constant region is from a human immunoglobulin light chain, such as a κ light chain or a λ light chain of a human immunoglobulin. In some embodiments, the constant region may include any modification disclosed herein or known in the art, such as insertion, deletion, substitution or chemical modification of amino acids. In some embodiments, the constant region includes a mutation that changes the effector function. In some embodiments, any amino acid residue of the constant region can be substituted with an amino acid residue of any allotype. In some specific embodiments, the monospecific antibody binding to CLDN18.2 includes: a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 73, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83. In some specific embodiments, the monospecific antibody that binds to CLDN18.2 comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 75, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83. In some specific embodiments, the monospecific antibody that binds to CLDN18.2 comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 77, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83. In some specific embodiments, the monospecific antibody that binds to CLDN18.2 comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 79, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83. In some specific embodiments, the monospecific antibody that binds to CLDN18.2 comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 81, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 83. In some specific embodiments, the monospecific antibody that binds to CLDN18.2 comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 85, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 89. In some specific embodiments, the monospecific antibody that binds to CLDN18.2 comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:87, and a light chain comprising the amino acid sequence shown in SEQ ID NO:89.
[0188] Tables S1 and S2 provide some exemplary monospecific antibodies that bind to CLDN18.2 (e.g., chimeric antibodies xi22F12, xi28G3, xi40F6, xi34G6, and xi10D8 and humanized antibodies hu22F12-1.1, hu22F12-1.2, hu22F12-1.3, hu22F12-1.4, hu22F12-1.5, hu28G3-1.2, and hu28G3-1.5) CDR and amino acid sequence information of the variable region. These exemplary antibodies can be used to construct the bispecific antibodies disclosed herein.
[0189] Table S1. Amino acid sequences of CDRs and variable regions (SEQ ID NO:
[0190]
[0191] The monospecific antibodies or antigen-binding portions thereof that bind to CLDN18.2 of the present disclosure may bind to human CLDN18.2. In some embodiments, the monospecific antibodies or antigen-binding portions thereof do not bind or substantially do not bind to CLDN18.1 (eg, human CLDN18.1).
[0192] Isolated nucleic acids
[0193] The present disclosure provides an isolated nucleic acid comprising a nucleotide sequence encoding a monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 as described in the present disclosure. Some nucleotide sequences encoding monospecific antibodies or antigen-binding portions thereof that bind to CLDN18.2 are exemplarily listed in the sequence listing.
[0194] Carrier
[0195] The present disclosure provides a vector comprising the nucleic acid. In some embodiments, the vector is a cloning vector; in other embodiments, the vector is an expression vector, and in a specific example, the expression vector is pcDNA3.1(+). The expression vector can be any expression vector capable of expressing the monospecific antibody binding to CLDN18.2 described in the present disclosure.
[0196] Host cells
[0197] The present disclosure provides host cells comprising nucleic acids of the present disclosure or vectors of the present disclosure. In some embodiments, the host cell is a suitable host cell for cloning or expressing a monospecific antibody or an antigen-binding portion thereof. In some embodiments, the host cell is a prokaryotic cell. In other embodiments, the host cell is a eukaryotic cell. In some embodiments, the host cell is selected from yeast cells, mammalian cells, or other cells suitable for preparing monospecific antibodies or antigen-binding portions thereof. Mammalian cells are, for example, Chinese hamster ovary (CHO) cells, CHO-S cells.
[0198] Antibody Drug Conjugates (ADC)
[0199] The present disclosure provides an antibody drug conjugate comprising a monospecific antibody or antigen binding portion thereof that binds to CLDN18.2 of the present disclosure. In some embodiments, the antibody drug conjugate comprises the monospecific antibody or antigen binding portion thereof that binds to CLDN18.2, and a cytotoxic drug. The monospecific antibody or antigen binding portion thereof that binds to CLDN18.2 and the cytotoxic drug are preferably connected by a linker, which is a cleavable linker or a non-cleavable linker.
[0200] Chimeric Antigen Receptor (CAR)
[0201] The present disclosure also provides an anti-CLDN18.2 chimeric antigen receptor (CAR) comprising the monospecific antibody or antigen-binding portion thereof that binds to CLDN18.2 of the present disclosure.
[0202] The anti-CLDN18.2 CAR may comprise (a) an extracellular antigen binding domain that binds to CLDN18.2; (b) a transmembrane domain; and (c) an intracellular signaling domain.
[0203] The present disclosure also provides engineered immune effector cells comprising the CAR of the present disclosure. In some embodiments, the immune effector cells are T cells, NK cells, peripheral blood mononuclear cells (PBMC), hematopoietic stem cells, pluripotent stem cells or embryonic stem cells.
[0204] Pharmaceutical composition
[0205] The present disclosure provides a pharmaceutical composition comprising a monospecific antibody or antigen-binding portion thereof, an antibody-drug conjugate or an engineered immune effector cell that binds to CLDN18.2 of the present disclosure, and further comprising one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients include, for example, excipients, diluents, encapsulating materials, fillers, buffers or other agents.
[0206] Methods for preparing monospecific antibodies or antigen-binding portions thereof
[0207] In some embodiments, the present disclosure provides a method for preparing a monospecific antibody or an antigen-binding portion thereof that binds to CLDN18.2, the method comprising: culturing the host cell to express the monospecific antibody or the antigen-binding portion thereof, and isolating and purifying the monospecific antibody or the antigen-binding portion thereof in the system. In order to produce the monospecific antibody or the antigen-binding portion thereof, the nucleic acid encoding the monospecific antibody or the antigen-binding portion thereof is isolated and inserted into one or more vectors for further cloning and / or expression in the host cell. The nucleic acid can be obtained by various methods known in the art such as gene splicing and chemical synthesis.
[0208] The purity of the monospecific antibodies, or antigen-binding portions thereof, can be determined by any of a number of well-known analytical methods, such as gel electrophoresis, high performance liquid chromatography, size exclusion chromatography, and the like.
[0209] The physicochemical properties and / or biological activities of the monospecific antibodies or antigen-binding portions thereof of the present disclosure can be identified, screened or characterized by a variety of assays known in the art.
[0210] use
[0211] The present disclosure provides the use of the monospecific antibodies or antigen binding portions thereof that bind to CLDN18.2 of the present disclosure. In some specific embodiments, the monospecific antibodies used may be xi22F12, hu22F12-1.1, hu22F12-1.2, hu22F12-1.3, hu22F12-1.4, hu22F12-1.5, xi28G3, hu28G3-1.2, hu28G3-1.5, xi40F6, xi34G6 or / and xi10D8.
[0212] The present disclosure provides the use of the monospecific antibody or its antigen binding portion, the antibody drug conjugate, the engineered immune effector cell or the pharmaceutical composition in the preparation of a medicament for treating a disease expressing CLDN18.2. In some embodiments, the monospecific antibody or its antigen binding portion, the antibody drug conjugate, the engineered immune effector cell or the pharmaceutical composition is prepared with one or more additional therapeutic agents. The additional therapeutic agent may be a tumor therapeutic agent known in the art.
[0213] The present disclosure provides a method for treating a disease expressing CLDN18.2, comprising administering the monospecific antibody or antigen-binding portion thereof, the antibody drug conjugate, the engineered immune effector cell, or the pharmaceutical composition to a subject in need thereof. In some embodiments, the disease is a tumor.
[0214] The present disclosure provides a method for treating a disease expressing CLDN18.2, comprising administering a therapeutically effective amount of the monospecific antibody or antigen-binding portion thereof, the antibody drug conjugate, the engineered immune effector cell, or the pharmaceutical composition to a subject in need thereof. In some embodiments, the disease is a tumor.
[0215] In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a non-solid tumor. In some embodiments, the tumor is gastric cancer, esophageal cancer, gastrointestinal cancer (e.g., colorectal cancer, including colon cancer and rectal cancer), pancreatic cancer, liver cancer, lung cancer (including small cell lung cancer and non-small cell lung cancer), bronchial cancer, mesothelioma, kidney cancer, ovarian cancer (including Krukenberg tumor), breast cancer, bladder cancer, uterine cancer (including endometrial cancer), prostate cancer, testicular cancer, anal cancer, vaginal cancer, bile duct cancer, gallbladder cancer, head and neck cancer, spinal tumors, otolaryngology tumors, thyroid cancer, mesothelioma, bone cancer, skin cancer, melanoma, adenocarcinoma, sarcoma, neuroblastoma, glioblastoma, brain cancer, central nervous system cancer, neuroendocrine tumors, leukemia, lymphoma and myeloma.
[0216] III. Bispecific Antibodies
[0217] The present disclosure provides a bispecific antibody comprising a first antigen binding portion that binds to CLDN18.2 and a second antigen binding portion that binds to CD3, wherein the first antigen binding portion comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 17, 25 or 33, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, 10, 18, 26 or 34, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, 11, 19, 27 or 35, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, 12, 20, 28 or 36, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, 13, 21, 29 or 37, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6, 14, 22, 30 or 38.
[0218] In some embodiments, the first antigen binding portion comprises: HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; wherein X1 Select from N or Q, X 2 is selected from S or T. In some specific embodiments, the X 1 is N, and X 2 is S. In some specific embodiments, the X 1 is N, and X 2 is T. In some specific embodiments, the X 1 is Q, and X 2 For S.
[0219] In some embodiments, the first antigen binding portion comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0220] In some embodiments, the first antigen binding portion comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:60, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0221] In some embodiments, the first antigen binding portion comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0222] In some embodiments, the first antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0223] In some embodiments, the first antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.
[0224] In some embodiments, the first antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:25, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:26, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:27, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:28, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:30.
[0225] In some embodiments, the first antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:38.
[0226] The present disclosure also provides a bispecific antibody comprising a first antigen binding portion that binds to CLDN18.2 and a second antigen binding portion that binds to CD3, wherein the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region whose amino acid sequence is shown in SEQ ID NO: 7, 15, 23, 31, 39, 67 or 71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region whose amino acid sequence is shown in SEQ ID NO: 8, 16, 24, 32, 40, 68 or 72.
[0227] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:8.
[0228] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:15, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:16.
[0229] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:24.
[0230] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:32.
[0231] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:40.
[0232] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:62, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0233] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0234] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0235] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0236] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:68.
[0237] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 67, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 68; wherein X 3 Selected from I or L, X 4 Select from N or Q, X 5 Select from S or T, X 6 Select from V or L, X 7 Select from T or S, X 8 Select from V or K, X 9 Select from T or N.
[0238] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:69, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:72.
[0239] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:72.
[0240] In some embodiments, the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 72; wherein X 10 Selected from V or I, X 11 Select from A or T, X 12 Select from Q or K, X 13 Select from T or R, X 14 Select from S or N.
[0241] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:7, 15, 23, 31, 39, 62, 63, 64, 65, 66, 67, 69, 70 or 71, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8, 16, 24, 32, 40, 68 or 72.
[0242] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8. Further, in some such embodiments, the first antigen binding portion also comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0243] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:15, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:16. Further, in some such embodiments, the first antigen binding portion also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0244] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24. Further, in some such embodiments, the first antigen binding portion also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.
[0245] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:32. Further, in some such embodiments, the first antigen binding portion also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:25, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:26, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:27, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:28, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:30.
[0246] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40. Further, in some such embodiments, the first antigen binding portion also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:38.
[0247] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:62, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the first antigen binding portion also comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0248] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the first antigen binding portion also comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0249] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the first antigen binding portion also comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0250] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the first antigen binding portion also comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:60, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0251] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68. Further, in some such embodiments, the first antigen binding portion also comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0252] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:67, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:68; wherein X 3 Selected from I or L, X 4 Select from N or Q, X 5 Select from S or T, X 6 Select from V or L, X 7 Select from T or S, X 8 Select from V or K, X 9 is selected from T or N. Further, in some such embodiments, the first antigen binding portion further comprises: HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; wherein X 1 Select from N or Q, X 2 Select from S or T.
[0253] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72. Further, in some such embodiments, the first antigen binding portion also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0254] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72. Further, in some such embodiments, the first antigen binding portion also comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0255] In some embodiments, the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:71, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:72; wherein X 10 Selected from V or I, X 11 Select from A or T, X 12 Select from Q or K, X 13 Select from T or R, X 14 is selected from S or N. Further, in some such embodiments, the first antigen binding portion further comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14.
[0256] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:7, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:8.
[0257] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:15, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:16.
[0258] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:23, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:24.
[0259] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:32.
[0260] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:40.
[0261] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:62, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0262] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0263] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0264] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0265] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0266] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:67, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:68.
[0267] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0268] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0269] In some embodiments, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:71, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0270] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:7, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:8.
[0271] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:15, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:16.
[0272] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:23, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:24.
[0273] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:31, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:32.
[0274] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:40.
[0275] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:62, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:68.
[0276] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:68.
[0277] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:68.
[0278] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:68.
[0279] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:68.
[0280] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:67, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:68.
[0281] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:69, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:72.
[0282] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:72.
[0283] In some specific embodiments, the first antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:71, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:72.
[0284] In the present disclosure, the first antigen binding portion is murine, chimeric or humanized. Humanization can reduce immunogenicity. Therefore, in some embodiments, the first antigen binding portion is humanized.
[0285] The exemplary monospecific antibodies provided in Tables S1 and S2 can be used to construct the bispecific antibodies of the present disclosure. For example, in some embodiments, the CDR of the first antigen-binding portion of the bispecific antibody is selected from the six CDRs of any exemplary monospecific antibody that binds to CLDN18.2. For example, in some embodiments, the variable region of the first antigen-binding portion of the bispecific antibody is selected from the heavy chain variable region and the light chain variable region of any exemplary monospecific antibody that binds to CLDN18.2.
[0286] In the bispecific antibodies of the present disclosure, the second antigen binding moiety provides the ability to target CD3. The second antigen binding moiety can be Fab, scFv or scFab (single-chain Fab). In some embodiments, the second antigen binding moiety is a scFv that binds CD3.
[0287] In some embodiments, the second antigen binding portion is murine, chimeric or humanized. In some embodiments, the second antigen binding portion is humanized. In some specific embodiments, the first antigen binding portion and the second antigen binding portion are both humanized.
[0288] In some embodiments, the second antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:98, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:99, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:100, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:101, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:102, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:103.
[0289] In some embodiments, the second antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:104, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:105.
[0290] In some embodiments, the second antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 104, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the second antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 104, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 105. In some embodiments, the second antigen binding portion comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:104, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:105.
[0291] In some specific examples, the bispecific antibody disclosed herein may be CNC39-L6 or CNC41-L6.
[0292] The bispecific antibodies of the present disclosure may bind to CLDN18.2. In some embodiments, the bispecific antibodies may bind to human CLDN18.2. In some embodiments, the bispecific antibodies do not bind or substantially do not bind to CLDN18.1 (eg, human CLDN18.1).
[0293] The bispecific antibodies disclosed herein can target CLDN18.2 expressed on the surface of tumor cells, and can also bind to T cells, induce T cell activation, and activate the tumor killing activity of T cells. The bispecific antibodies disclosed herein exhibit excellent anti-tumor properties such as lysing tumor cells or inhibiting tumor cell proliferation. In some embodiments, the bispecific antibodies have excellent anti-tumor properties against tumors (e.g., gastric cancer, pancreatic cancer, etc.).
[0294] The molecular design of the bispecific antibodies disclosed herein facilitates expression and purification.
[0295] The bispecific antibodies disclosed herein have good safety.
[0296] Bispecific antibody configuration
[0297] The bispecific antibodies of the present disclosure may be Fc domain-less, with the first antigen-binding moiety and the second antigen-binding moiety fused via a suitable linker.
[0298] The bispecific antibodies of the present disclosure may have an Fc domain, which may extend half-life, provide Fc domain-related effector functions, etc. In some embodiments, the first antigen-binding portion and / or the second antigen-binding portion of the bispecific antibodies of the present disclosure may be fused to the N-terminus of the Fc domain.
[0299] In the bispecific antibodies disclosed herein, the first antigen binding moiety and the second antigen binding moiety may adopt any suitable structural form. In some embodiments, the first antigen binding moiety and the second antigen binding moiety may each independently be Fab, scFv, scFab or other structures.
[0300] The bispecific antibodies of the present disclosure can be multivalent, such as bivalent, tetravalent, etc. In some embodiments, the bispecific antibodies are bivalent, that is, the first antigen binding moiety and the second antigen binding moiety each provide monovalent binding to the corresponding antigen.
[0301] In some embodiments, the first antigen binding moiety is a Fab and the second antigen binding moiety is a scFv.
[0302] In some embodiments, the bispecific antibodies of the present disclosure further comprise an Fc domain composed of two Fc polypeptides.
[0303] In some embodiments, the first antigen binding moiety is Fab, the second antigen binding moiety is scFv, the first antigen binding moiety is fused at the C-terminus of its Fab heavy chain to the N-terminus of one of the Fc polypeptides of the Fc domain, and the second antigen binding moiety is fused at its C-terminus to the N-terminus of another Fc polypeptide of the Fc domain. Such a configuration is schematically described in Figure 3 In this embodiment, in a further more specific embodiment, the bispecific antibody is composed of three polypeptide chains, wherein the first polypeptide chain contains the Fab light chain of the first antigen binding moiety, the second polypeptide chain contains the Fab heavy chain of the first antigen binding moiety and one of the Fc polypeptides of the Fc domain, and the third polypeptide chain contains the second antigen binding moiety and another Fc polypeptide of the Fc domain.
[0304] In the bispecific antibody disclosed herein, the heavy chain variable region and the light chain variable region of the second antigen binding moiety are connected via a peptide linker to form scFv. The peptide linker may be any suitable linker, such as a charged and / or flexible linker.
[0305] In some embodiments, the second antigen binding moiety is a scFv, and its structure from N-terminus to C-terminus is VH-VL. In some embodiments, the second antigen binding moiety is a scFv, and its structure from N-terminus to C-terminus is VL-VH. Optionally, the heavy chain variable region of the second antigen binding moiety is fused to the light chain variable region of the second antigen binding moiety via a peptide linker.
[0306] In some specific embodiments, the peptide linker consists of 1 to 50 amino acids connected by peptide bonds, wherein the amino acids can be selected from 20 naturally occurring amino acids. In some more preferred embodiments, 1 to 50 amino acids are selected from glycine, alanine, proline, serine, asparagine, glutamine and lysine. Thus, an exemplary peptide linker can be polyglycine (especially (Gly) 4 、(Gly) 5 ), poly(Gly-Ser), (Gly) 3 AsnGlySer(Gly) 2 、(Gly) 3 Cys(Gly) 4 , GlyProAsnGlyGly, etc.
[0307] In some embodiments, the peptide linker can be a peptide linker composed of lysine, proline, glycine and serine. In some embodiments, the number of amino acids contained in the peptide linker can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more than 20. In some embodiments, the peptide linker is a peptide linker containing GKPGS as a unit. In some embodiments, the peptide linker in the unit of GKPGS is (GKPGS) n , wherein n is any number between 1-10, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, or any range defined by any two of the foregoing numbers, such as 1-5, 2-5, 3-6, 2-4, 1-4, etc. In some specific embodiments, the peptide linker is a peptide comprising GKPGS (SEQ ID NO: 108), (GKPGS) 2 、(GKPGS) 3 or (GKPGS) 4 In some specific embodiments, the heavy chain variable region of the second antigen binding moiety is linked to the second antigen binding moiety via a peptide linker (GKPGS) 4 Fused to the light chain variable region of a second antigen binding moiety.
[0308] In some specific embodiments, the first antigen binding moiety is Fab, the second antigen binding moiety is scFv, the first antigen binding moiety is fused at the C-terminus of its Fab heavy chain to the N-terminus of one of the Fc polypeptides of the Fc domain, the light chain variable region of the second antigen binding moiety is fused at its C-terminus to the N-terminus of another Fc polypeptide of the Fc domain, and the heavy chain variable region of the second antigen binding moiety is fused at its C-terminus to the light chain variable region of the second antigen binding moiety; preferably, the heavy chain variable region of the second antigen binding moiety is fused via a peptide linker (GKPGS) 4 Fused to the light chain variable region of a second antigen binding moiety.
[0309] When fused to Fc, it is typically fused through the hinge region. In one embodiment, the first antigen binding moiety is fused to one of the Fc polypeptides of the Fc domain via the first hinge, and the second antigen binding moiety is fused to another Fc polypeptide of the Fc domain via the second hinge. In some embodiments, the first hinge and the second hinge can form a covalent bond with each other, such as a disulfide bond. The first hinge or / and the second hinge may comprise amino acids from the hinge region of human IgG, the hinge region of human IgG comprising a natural hinge region or a variant thereof. In some embodiments, the first hinge or / and the second hinge comprise amino acids from the hinge region of human IgG1. In some embodiments, the first hinge or / and the second hinge comprise amino acids from the hinge region of human IgG4. In some specific embodiments, the first hinge comprises EPKSCDKTHTCPPCP (SEQ ID NO: 106) and the second hinge comprises GEPKSSDKTHTCPPCP (SEQ ID NO: 107).
[0310] In other embodiments, the first antigen binding moiety is Fab, the second antigen binding moiety is scFv, the first antigen binding moiety is fused at the C-terminus of its Fab light chain to the N-terminus of one of the Fc polypeptides of the Fc domain, and the second antigen binding moiety is fused at its C-terminus to the N-terminus of another Fc polypeptide of the Fc domain.
[0311] Fc domain
[0312] The Fc domain of a bispecific antibody is composed of a pair of polypeptide chains comprising the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each of which Fc polypeptides comprises the CH2 and CH3 of the IgG heavy chain constant region. The two Fc polypeptides of the Fc domain can stably associate with each other. In some embodiments, the bispecific antibody of the present disclosure comprises one Fc domain.
[0313] In some embodiments, the Fc domain of the bispecific antibody is an IgG Fc domain. In some embodiments, the Fc domain is an IgG1 Fc domain. In some embodiments, the Fc domain is a human IgG Fc domain. In some specific embodiments, the Fc domain is a human IgG1 Fc domain.
[0314] In some embodiments, the Fc domain comprises a modification, such as an amino acid substitution, which can be, for example, a modification that promotes heterodimerization, a modification that changes effector function, or a modification that changes the ability to bind to protein A.
[0315] In some embodiments, the Fc comprises modifications that promote heterodimerization.
[0316] The bispecific antibodies of the present disclosure comprise different antigen binding moieties fused to one or the other of the two Fc polypeptides in the Fc domain, and therefore, the two Fc polypeptides are generally contained in two different polypeptide chains. The recombinant co-expression of these polypeptides and the subsequent dimerization produce several possible combinations of the two polypeptides. In order to improve the yield and purity of the bispecific antibodies in recombinant production, it would be advantageous to introduce modifications that promote the desired polypeptide binding in the Fc domain of the bispecific antibodies. Therefore, in a specific embodiment, the Fc domain comprises an amino acid substitution that promotes the association of the two Fc polypeptides of the Fc domain.
[0317] The site of the most extensive protein-protein interaction between the two Fc polypeptides of the human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one embodiment, the modification is in the CH3 domain of the Fc domain.
[0318] In a specific embodiment, the modification is a so-called "knob-into-hole" modification, which comprises a "knob" modification in one of the two Fc polypeptides of the Fc domain and a "hole" modification in the other of the two Fc polypeptides of the Fc domain. Generally, the method involves introducing a protrusion ("knob") at the interface of one Fc polypeptide and a corresponding depression ("hole") at the interface of the other Fc polypeptide, such that the protrusion can be positioned in the depression to promote heterodimer formation and hinder homodimer formation. The protrusion is constructed by replacing a small amino acid side chain from the interface of one Fc polypeptide with a larger side chain (e.g., tyrosine or tryptophan, etc.). A complementary depression having the same or similar size as the protrusion is generated in the interface of the other Fc polypeptide by replacing a large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine, etc.).
[0319] Thus, in a specific embodiment, in the CH3 domain of one Fc polypeptide of the bispecific antibody, amino acid residues are substituted with amino acid residues having a larger side chain volume, thereby generating a protrusion in the CH3 domain of the Fc polypeptide that can be positioned in a depression in the CH3 domain of the other Fc polypeptide, and in the CH3 domain of the other Fc polypeptide, amino acid residues are substituted with amino acid residues having a smaller side chain volume, thereby generating a depression in the CH3 domain of the Fc polypeptide.
[0320] In some embodiments, according to EU numbering, one Fc polypeptide of the Fc domain comprises amino acid substitutions 354C or / and 366Y / W, and the other Fc polypeptide comprises amino acid substitutions 349C, 366S, 368A or / and 407T / V. In some specific embodiments, according to EU numbering, one of the Fc polypeptides of the Fc domain comprises amino acid substitutions 354C and 366Y / W, and the other Fc polypeptide comprises amino acid substitutions 349C, 366S, 368A, and 407T / V. In some more specific embodiments, according to EU numbering, one of the Fc polypeptides of the Fc domain comprises amino acid substitutions 354C and 366W, and the other Fc polypeptide comprises amino acid substitutions 349C, 366S, 368A, and 407V. In the above embodiments, Fc can be human IgG1 Fc. In a specific embodiment, according to EU numbering, one of the Fc polypeptides of the Fc domain comprises amino acid substitutions S354C and T366W and the other Fc polypeptide comprises amino acid substitutions Y349C, T366S, L368A, and Y407V.
[0321] In some embodiments, the Fc domain comprises a modification that changes effector function. In some specific embodiments, the Fc domain of the bispecific antibody is modified to reduce the binding affinity of the Fc domain to the Fc receptor and / or reduce the effector function compared to the Fc without the modification. Reducing the binding affinity of the Fc domain to the Fc receptor and / or reducing the effector function is beneficial to improving cytokine release and side effects.
[0322] In some embodiments, the modification that reduces the binding affinity of the Fc domain to the Fc receptor and / or reduces effector function is an amino acid substitution. In some embodiments, the Fc domain comprises an amino acid substitution at one or more positions selected from 233, 234, 235, 297, 331 and 329. In some embodiments, the Fc domain comprises an amino acid substitution at one or more positions selected from 234, 235 and 329. In some embodiments, the Fc domain comprises an amino acid substitution 234A and 235A. In one such embodiment, the Fc is an IgG1 Fc, especially a human IgG1 Fc. In some embodiments, the Fc domain comprises an amino acid substitution at position 329. In a more specific embodiment, the amino acid substitution is 329A, 329R or 329G. In some embodiments, the Fc domain comprises an amino acid substitution at position 329 and additional amino acid substitutions at positions selected from 233, 234, 235, 297 and 331. In a more specific embodiment, the additional amino acid substitution is 233P, 234A, 235A, 235E, 297A, 297D or / and 331S. In some embodiments, the Fc domain comprises amino acid substitutions at positions 329, 234 and 235. In a more specific embodiment, the Fc domain comprises amino acid substitutions 234A, 235A and 329G. In another more specific embodiment, the Fc domain comprises amino acid substitutions 234A, 235A and 329A. In one such embodiment, the Fc is an IgG1 Fc, especially a human IgG1 Fc. In a specific embodiment, the Fc domain comprises amino acid substitutions L234A, L235A and P329G. In another specific embodiment, the Fc domain comprises amino acid substitutions L234A, L235A and P329A.
[0323] In some specific embodiments, the Fc domain is a human IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329A / G / R. Further, the Fc domain is a human IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329A.
[0324] The amino acid substitutions described above that reduce the binding affinity of the Fc domain to the Fc receptor and / or reduce the effector function occur on the two polypeptide chains of the Fc domain.
[0325] In some embodiments, the Fc domain comprises a modification that reduces or eliminates the binding of the CH3 region of one Fc polypeptide in the Fc domain to Protein A (Protein A from Staphylococcus aureus). In some embodiments, the Fc domain comprises an amino acid substitution that reduces or eliminates the binding of the CH3 region of one Fc polypeptide in the Fc domain to Protein A. In some embodiments, according to EU numbering, the Fc domain comprises an amino acid substitution (a) 435R or (b) 435R and 436F, which occurs only on one Fc polypeptide and not on another Fc polypeptide. In some embodiments, according to EU numbering, the Fc domain comprises an amino acid substitution (a) 435R or (b) 435R and 436F that occurs only in one of the Fc polypeptides. In some specific embodiments, according to EU numbering, the Fc domain comprises an amino acid substitution H435R and Y436F that occurs only in one of the Fc polypeptides. In some specific embodiments, according to EU numbering, the Fc domain comprises an amino acid substitution H435R that occurs only in one of the Fc polypeptides. In the above embodiments, the Fc is IgG1 Fc, in particular human IgG1 Fc.
[0326] In the bispecific antibodies disclosed herein, the Fc domain may include one, two or three of modifications that promote heterodimerization, modifications that change effector functions, and modifications that reduce or eliminate the binding of a CH3 region of an Fc polypeptide in the Fc domain to protein A. In some embodiments, the Fc comprises modifications that promote heterodimerization, modifications that change effector functions, and modifications that reduce or eliminate the binding of a CH3 region of an Fc polypeptide in the Fc domain to protein A. Specific schemes for the above-mentioned different types of modifications can be combined. For example, in a specific embodiment, according to EU numbering, the Fc domain comprises the following group of amino acid substitutions:
[0327] i. 349C, 366S, 368A, 407T / V, 354C and 366Y / W; wherein the amino acid substitutions 354C and 366Y / W are on the same Fc polypeptide, and are not on the same Fc polypeptide as the other amino acid substitutions in (i);
[0328] ii. 234A, 235A and 329A; and
[0329] iii. (a) 435R or (b) 435R and 436F, occurring on only one of the Fc polypeptides.
[0330] In a more specific embodiment, according to EU numbering, one of the Fc polypeptides of the Fc domain comprises the amino acid substitutions: L234A, L235A, P329A, Y349C, T366S, L368A and Y407V, and the other Fc polypeptide comprises the amino acid substitutions: L234A, L235A, P329A, S354C, T366W and H435R. In this specific embodiment, the Fc is IgG1 Fc, especially human IgG1 Fc.
[0331] In another more specific embodiment, according to EU numbering, one of the Fc polypeptides of the Fc domain comprises the amino acid substitutions: L234A, L235A, P329A, Y349C, T366S, L368A and Y407V, and the other Fc polypeptide comprises the amino acid substitutions: L234A, L235A, P329A, S354C, T366W, H435R and Y436F. In this specific embodiment, the Fc is IgG1 Fc, especially human IgG1 Fc.
[0332] In the context of the present disclosure, amino acid substitutions are represented as: original amino acid-position-substituted amino acid, using three-letter code (Xaa) or single-letter code (X) to represent the amino acid residue, and the original amino acid can be omitted. Therefore, for example, "H435R" or "435R" means that the amino acid H or the original amino acid at position 435 is replaced by amino acid R; the substituted amino acid may include more than one, for example, "T366Y / W" means that the amino acid T at position 366 is replaced by amino acid Y or W.
[0333] In some embodiments, the bispecific antibody is composed of three polypeptide chains, wherein one polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:91, another polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:83, and a third polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:84. The amino acid sequence shown in NO:95 has an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.
[0334] In some embodiments, the bispecific antibody is composed of three polypeptide chains, wherein one polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:93, another polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:89, and a third polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:89. The amino acid sequence shown in NO:95 has an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.
[0335] In some embodiments, the bispecific antibody is composed of three polypeptide chains, one polypeptide chain comprising the amino acid sequence shown in SEQ ID NO:91, another polypeptide chain comprising the amino acid sequence shown in SEQ ID NO:83, and a third polypeptide chain comprising the amino acid sequence shown in SEQ ID NO:95.
[0336] In some embodiments, the bispecific antibody is composed of three polypeptide chains, one polypeptide chain comprising the amino acid sequence shown in SEQ ID NO:93, another polypeptide chain comprising the amino acid sequence shown in SEQ ID NO:89, and a third polypeptide chain comprising the amino acid sequence shown in SEQ ID NO:95.
[0337] The present disclosure provides exemplary bivalent, bispecific antibodies.
[0338] In one example, the bispecific antibody is composed of three polypeptide chains, and the amino acid sequences of the three polypeptide chains are shown in SEQ ID NOs: 91, 83, and 95, respectively. In some embodiments, the nucleotide sequences encoding the three polypeptide chains are shown in SEQ ID NOs: 92, 84, and 96, respectively.
[0339] In one example, the bispecific antibody is composed of three polypeptide chains, and the amino acid sequences of the three polypeptide chains are shown in SEQ ID NOs: 93, 89, and 95, respectively. In some embodiments, the nucleotide sequences encoding the three polypeptide chains are shown in SEQ ID NOs: 94, 90, and 96, respectively.
[0340] Isolated nucleic acids
[0341] The present disclosure provides an isolated nucleic acid comprising a nucleotide sequence encoding the bispecific antibody of the present disclosure. Some nucleotide sequences encoding bispecific antibodies are exemplarily listed in the sequence listing.
[0342] Carrier
[0343] The present disclosure provides a vector comprising the nucleic acid. In some embodiments, the vector is a cloning vector; in other embodiments, the vector is an expression vector, and in a specific example, the expression vector is pcDNA3.1(+). The expression vector can be any expression vector capable of expressing the bispecific antibody of the present disclosure.
[0344] Host cells
[0345] The present disclosure provides host cells comprising nucleic acids of the present disclosure or vectors of the present disclosure. In some embodiments, the host cell is a suitable host cell for cloning or expressing bispecific antibodies. In some embodiments, the host cell is a prokaryotic cell. In other embodiments, the host cell is a eukaryotic cell. In some embodiments, the host cell is selected from yeast cells, mammalian cells, or other cells suitable for preparing bispecific antibodies. Mammalian cells are, for example, Chinese hamster ovary (CHO) cells, CHO-S cells.
[0346] Pharmaceutical composition
[0347] The present disclosure provides a pharmaceutical composition comprising the bispecific antibody of the present disclosure and further comprising one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients include, for example, excipients, diluents, encapsulating materials, fillers, buffers or other agents.
[0348] Methods for preparing bispecific antibodies
[0349] In some embodiments, the present disclosure provides a method for preparing a bispecific antibody, the method comprising: culturing the host cell to express the bispecific antibody, and separating and purifying the bispecific antibody in the system. In order to produce the bispecific antibody, the nucleic acid encoding the bispecific antibody is separated and inserted into one or more vectors for further cloning and / or expression in the host cell. The nucleic acid can be obtained by various methods known in the art such as gene splicing and chemical synthesis.
[0350] The prepared bispecific antibodies can be purified by techniques known in the art, such as high performance liquid chromatography, ion exchange chromatography, gel chromatography, affinity chromatography, size exclusion chromatography, ceramic hydroxyapatite (CHT) chromatography, and the like. The actual conditions used to purify a particular protein depend in part on factors such as net charge, hydrophobicity, hydrophilicity, and these are apparent to those skilled in the art. For affinity chromatography, an antibody, ligand, receptor, or antigen that binds to the bispecific antibody can be used for purification. For example, for affinity chromatography of the bispecific antibodies of the present disclosure, a matrix with protein A or protein G can be used for purification. Affinity chromatography, ion exchange chromatography, gel chromatography, or / and CHT chromatography can be used continuously to purify the bispecific antibodies of the present disclosure.
[0351] The purity of the bispecific antibody can be determined by any of a number of well-known analytical methods, such as gel electrophoresis, high performance liquid chromatography, size exclusion chromatography, and the like.
[0352] The physicochemical properties and / or biological activities of the bispecific antibodies of the present disclosure can be identified, screened or characterized by various assay methods known in the art.
[0353] use
[0354] The present disclosure provides uses of the bispecific antibodies of the present disclosure. In some specific embodiments, the bispecific antibodies used may be CNC39-L6 or / and CNC41-L6.
[0355] The present disclosure provides the use of the bispecific antibody or the pharmaceutical composition in the preparation of a medicament for treating a disease expressing CLDN18.2. In some embodiments, the bispecific antibody or the pharmaceutical composition is used with one or more additional therapeutic agents to prepare the medicament. The additional therapeutic agent may be a tumor therapeutic agent known in the art.
[0356] The present disclosure provides a method for treating a disease expressing CLDN18.2, comprising administering the bispecific antibody or the pharmaceutical composition to a subject in need thereof. In some embodiments, the disease is a tumor.
[0357] The present disclosure provides a method for treating a disease expressing CLDN18.2, comprising administering a therapeutically effective amount of the bispecific antibody or the pharmaceutical composition to a subject in need thereof. In some embodiments, the disease is a tumor.
[0358] In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a non-solid tumor. In some embodiments, the tumor is gastric cancer, esophageal cancer, gastrointestinal cancer (e.g., colorectal cancer, including colon cancer and rectal cancer), pancreatic cancer, liver cancer, lung cancer (including small cell lung cancer and non-small cell lung cancer), bronchial cancer, mesothelioma, kidney cancer, ovarian cancer (including Krukenberg tumor), breast cancer, bladder cancer, uterine cancer (including endometrial cancer), prostate cancer, testicular cancer, anal cancer, vaginal cancer, bile duct cancer, gallbladder cancer, head and neck cancer, spinal tumors, otolaryngology tumors, thyroid cancer, mesothelioma, bone cancer, skin cancer, melanoma, adenocarcinoma, sarcoma, neuroblastoma, glioblastoma, brain cancer, central nervous system cancer, neuroendocrine tumors, leukemia, lymphoma and myeloma. BRIEF DESCRIPTION OF THE DRAWINGS
[0359] Figures 1A-1I The MFI of the anti-CLDN18.2 chimeric antibody binding to U2OS-CLDN18.2, KATOIII, and NUGC-4 cells was detected by FACS;
[0360] Figures 2A-2D The MFI of anti-CLDN18.2 humanized antibody binding to KATOIII, NUGC-4, and BxPC-3CLDN18.2 cells was detected by FACS;
[0361] Figure 3 is a schematic diagram of the structure of an exemplary bispecific antibody disclosed in the present invention;
[0362] Figures 4A-4C The MFI of the anti-CLDN18.2 / anti-CD3 bispecific antibody binding to different cells was detected by FACS. Figure 4A For KATOIII cells, Figure 4B For NUGC-4 cells, Figure 4C BxPC-3CLDN18.2 cells;
[0363] Figures 5A-5C is the lysis rate of anti-CLDN18.2 / anti-CD3 bispecific antibody on different cells, Figure 5A For KATOIII cells, Figure 5B For NUGC-4 cells, Figure 5C BxPC-3CLDN18.2 cells;
[0364] Figures 6A-6D is the effect of anti-CLDN18.2 / anti-CD3 bispecific antibody on T cell activation in the presence of target cell KATOIII, CD69 and CD25 are T cell activation markers, among which Fig. 6A CD25 + CD4 +The ratio of cell number, Figure 6B CD69 + CD4 + The ratio of cell number, Figure 6C CD25 + The number of cells accounted for CD8 + The ratio of cell number, Fig.6D CD69 + The number of cells accounted for CD8 + The ratio of cell number. DETAILED DESCRIPTION
[0365] The present disclosure also provides the following specific implementation schemes, but the protection scope of the present disclosure is not limited thereto:
[0366] Embodiment 1. A bispecific antibody comprising a first antigen binding portion that binds CLDN18.2 and a second antigen binding portion that binds CD3, wherein the first antigen binding portion comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, 9, 17, 25 or 33, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, 59, 10, 18, 26 or 34, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, 11, 19, 27 or 35, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, 12, 20, 28 or 36, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, 13, 21, 29 or 37, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6, 14, 22, 30 or 38.
[0367] Embodiment 2. The bispecific antibody of embodiment 1, wherein the first antigen binding portion comprises:
[0368] (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; wherein X 1 Select from N or Q, X 2 Select from S or T;
[0369] (2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6;
[0370] (3) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:60, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6;
[0371] (4) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:61, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6;
[0372] (5) a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14;
[0373] (6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22;
[0374] (7) a HCDR1 comprising the amino acid sequence of SEQ ID NO:25, a HCDR2 comprising the amino acid sequence of SEQ ID NO:26, a HCDR3 comprising the amino acid sequence of SEQ ID NO:27, a LCDR1 comprising the amino acid sequence of SEQ ID NO:28, a LCDR2 comprising the amino acid sequence of SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:30; or
[0375] (8) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:38.
[0376] Embodiment 3. A bispecific antibody comprising a first antigen binding portion that binds to CLDN18.2 and a second antigen binding portion that binds to CD3, wherein the first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 63, 69, 7, 15, 23, 31, 39, 67 or 71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 68, 72, 8, 16, 24, 32 or 40.
[0377] Embodiment 4. The bispecific antibody of embodiment 3, wherein the first antigen binding portion comprises:
[0378] (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:68;
[0379] (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:69, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:72;
[0380] (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:8;
[0381] (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 15, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 16;
[0382] (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 24;
[0383] (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:32;
[0384] (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:40;
[0385] (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:62, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0386] (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68;
[0387] (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:68;
[0388] (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:68;
[0389] (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 67, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 68, wherein X 3 Selected from I or L, X 4 Select from N or Q, X 5 Select from S or T, X 6 Select from V or L, X 7 Select from T or S, X 8 Select from V or K, X 9 Select from T or N;
[0390] (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence of SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence of SEQ ID NO:72; or
[0391] (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 72, wherein X 10 Selected from V or I, X 11 Select from A or T, X 12 Select from Q or K, X 13 Select from T or R, X 14 Select from S or N.
[0392] Embodiment 5. The bispecific antibody of any one of embodiments 1-4, wherein the first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 63, 69, 7, 15, 23, 31, 39, 62, 64, 65, 66, 67, 70 or 71, and an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: The amino acid sequence shown in NO:68, 72, 8, 16, 24, 32 or 40 has a light chain variable region that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.
[0393] Embodiment 6. The bispecific antibody of any one of embodiments 1-5, wherein the first antigen binding portion comprises:
[0394] (1) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0395] (2) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72;
[0396] (3) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8;
[0397] (4) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:15, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:16;
[0398] (5) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24;
[0399] (6) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:32;
[0400] (7) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40;
[0401] (8) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:62, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0402] (9) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0403] (10) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0404] (11) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0405] (12) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0406] (13) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72; or
[0407] (14) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:71, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:72.
[0408] Embodiment 7. The bispecific antibody according to any one of embodiments 1-6, wherein the first antigen binding portion comprises: (1) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 63, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 68;
[0409] (2) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:72;
[0410] (3) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8;
[0411] (4) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16;
[0412] (5) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:23, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:24;
[0413] (6) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:32;
[0414] (7) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:40;
[0415] (8) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:62, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0416] (9) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:64, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0417] (10) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:65, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0418] (11) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:66, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0419] (12) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:67, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0420] (13) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 70, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 72; or
[0421] (14) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:71, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0422] Embodiment 8. The bispecific antibody according to embodiment 1, wherein the first antigen binding portion comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6.
[0423] Embodiment 9. The bispecific antibody of embodiment 8, wherein the first antigen binding portion comprises: a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 68; preferably, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 63, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 68.
[0424] Embodiment 10. The bispecific antibody according to embodiment 1, wherein the first antigen binding portion comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
[0425] Embodiment 11. The bispecific antibody of embodiment 10, wherein the first antigen binding portion comprises: a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 69, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 72; preferably, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 69, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 72.
[0426] Embodiment 12. A bispecific antibody according to any one of embodiments 1-11, wherein the second antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:98, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:99, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:100, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:101, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:102, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:103.
[0427] Embodiment 13. A bispecific antibody according to any one of Embodiments 1-11, wherein the second antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:104, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:105.
[0428] Embodiment 14. The bispecific antibody of any one of embodiments 1-13, wherein the second antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 104, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 105.
[0429] Embodiment 15. A bispecific antibody according to any one of Embodiments 1-13, wherein the second antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:104, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:105.
[0430] Embodiment 16. The bispecific antibody of any one of Embodiments 1-15, wherein the first antigen binding portion is murine, chimeric or humanized.
[0431] Embodiment 17. The bispecific antibody of any one of Embodiments 1-16, wherein the second antigen binding portion is murine, chimeric or humanized.
[0432] Embodiment 18. A bispecific antibody according to any one of Embodiments 1-17, wherein the first antigen binding portion and the second antigen binding portion are each independently Fab, scFv or scFab.
[0433] Embodiment 19. The bispecific antibody of Embodiment 18, wherein the first antigen binding portion is Fab and the second antigen binding portion is scFv.
[0434] Embodiment 20. The bispecific antibody according to any one of Embodiments 1-19, further comprising an Fc domain composed of two Fc polypeptides.
[0435] Embodiment 21. A bispecific antibody according to Embodiment 20, wherein the first antigen binding moiety is Fab, the second antigen binding moiety is scFv, the first antigen binding moiety is fused at the C-terminus of its Fab heavy chain to the N-terminus of one of the Fc polypeptides of the Fc domain, and the second antigen binding moiety is fused at its C-terminus to the N-terminus of another Fc polypeptide of the Fc domain.
[0436] Embodiment 22. The bispecific antibody according to any one of embodiments 19-21, wherein the structure of the second antigen binding moiety from N-terminus to C-terminus is VH-VL or VL-VH; optionally, the heavy chain variable region of the second antigen binding moiety is fused to the light chain variable region of the second antigen binding moiety via a peptide linker, preferably, the peptide linker is (GKPGS) 4 .
[0437] Embodiment 23. The bispecific antibody according to any one of Embodiments 20-22, wherein the Fc domain is an IgG Fc domain, preferably an IgG1 Fc domain.
[0438] Embodiment 24. The bispecific antibody according to Embodiment 23, wherein the IgG Fc domain is a human IgG Fc domain, preferably a human IgG1 Fc domain.
[0439] Embodiment 25. The bispecific antibody of any one of Embodiments 20-24, wherein the Fc domain comprises an amino acid substitution that promotes the association of two Fc polypeptides of the Fc domain.
[0440] Embodiment 26. The bispecific antibody of Embodiment 25, wherein, according to EU numbering, one of the Fc polypeptides of the Fc domain comprises amino acid substitutions 354C and 366Y / W and the other Fc polypeptide comprises amino acid substitutions 349C, 366S, 368A and 407T / V.
[0441] Embodiment 27. A bispecific antibody according to any one of Embodiments 20-26, wherein the Fc domain comprises an amino acid substitution that reduces the binding affinity of the Fc domain to an Fc receptor and / or reduces effector function.
[0442] Embodiment 28. A bispecific antibody according to embodiment 27, wherein the amino acid substitutions that reduce the binding affinity of the Fc domain to the Fc receptor and / or reduce effector function are at one or more positions selected from the group consisting of: 234, 235 and 329 according to EU numbering; preferably, both Fc polypeptides of the Fc domain contain amino acid substitutions 234A, 235A and 329G, or both contain amino acid substitutions 234A, 235A and 329A.
[0443] Embodiment 29. A bispecific antibody according to any one of embodiments 20-28, wherein the Fc domain comprises an amino acid substitution that reduces or eliminates the binding of the CH3 region of an Fc polypeptide in the Fc domain to protein A.
[0444] Embodiment 30. The bispecific antibody of Embodiment 29, wherein, according to EU numbering, the Fc domain comprises the amino acid substitutions (a) 435R or (b) 435R and 436F occurring in only one of the Fc polypeptides.
[0445] Embodiment 31. A bispecific antibody according to any one of embodiments 20-24, wherein, according to EU numbering, one of the Fc polypeptides of the Fc domain comprises the amino acid substitutions: L234A, L235A, P329A, Y349C, T366S, L368A and Y407V, and the other Fc polypeptide comprises the amino acid substitutions: (a) L234A, L235A, P329A, S354C, T366W and H435R, or (b) L234A, L235A, P329A, S354C, T366W, H435R and Y436F.
[0446] Embodiment 32. The bispecific antibody according to any one of Embodiments 1-31, wherein the bispecific antibody is bivalent.
[0447] Embodiment 33. The bispecific antibody according to any one of embodiments 1-32, wherein the bispecific antibody consists of three polypeptide chains, wherein:
[0448] (1) one polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:91, another polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:83, and a third polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:84. an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in NO:95; or
[0449] (2) one polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:93, another polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:89, and a third polypeptide chain comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:89. The amino acid sequence shown in NO:95 has an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.
[0450] Embodiment 34. A bispecific antibody, the bispecific antibody consisting of three polypeptide chains, wherein:
[0451] (1) one polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO:91, another polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO:83, and a further polypeptide chain comprises the amino acid sequence set forth in SEQ ID NO:95; or
[0452] (2) One polypeptide chain comprises the amino acid sequence shown in SEQ ID NO:93, another polypeptide chain comprises the amino acid sequence shown in SEQ ID NO:89, and another polypeptide chain comprises the amino acid sequence shown in SEQ ID NO:95.
[0453] Embodiment 35. An isolated nucleic acid comprising a nucleotide sequence encoding the bispecific antibody according to any one of embodiments 1-34.
[0454] Embodiment 36. A vector comprising the nucleic acid according to embodiment 35.
[0455] Embodiment 37. A host cell comprising the nucleic acid according to embodiment 35, or the vector according to embodiment 36.
[0456] Embodiment 38. A method for preparing a bispecific antibody according to any one of embodiments 1-34, comprising culturing the host cell according to embodiment 37 to express the bispecific antibody, and isolating and purifying the bispecific antibody in the system.
[0457] Embodiment 39. A pharmaceutical composition comprising the bispecific antibody according to any one of Embodiments 1-34, and a pharmaceutically acceptable excipient.
[0458] Embodiment 40. Use of the bispecific antibody according to any one of Embodiments 1-34 or the pharmaceutical composition according to Embodiment 39 for the preparation of a medicament for treating a disease expressing CLDN18.2.
[0459] Embodiment 41. The use according to embodiment 40, wherein the disease is a tumor; preferably, the tumor is a solid tumor or a non-solid tumor; more preferably, the tumor is gastric cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, liver cancer, lung cancer, bronchial cancer, mesothelioma, kidney cancer, ovarian cancer, breast cancer, bladder cancer, uterine cancer, prostate cancer, testicular cancer, anal cancer, vaginal cancer, bile duct cancer, gallbladder cancer, head and neck cancer, spinal tumors, otolaryngology tumors, thyroid cancer, mesothelioma, bone cancer, skin cancer, melanoma, adenocarcinoma, sarcoma, neuroblastoma, glioblastoma, brain cancer, central nervous system cancer, neuroendocrine tumors, leukemia, lymphoma and myeloma.
[0460] Embodiment 42. The use according to Embodiment 40 or 41, wherein the bispecific antibody or the pharmaceutical composition is combined with one or more additional therapeutic agents to prepare the medicament.
[0461] Embodiment 43. A method for treating a disease expressing CLDN18.2, comprising administering a therapeutically effective amount of the bispecific antibody according to any one of Embodiments 1-34 or the pharmaceutical composition according to Embodiment 39 to a subject in need thereof.
[0462] Embodiment 44. The method according to Embodiment 43, wherein the disease is a tumor; preferably, the tumor is a solid tumor or a non-solid tumor; more preferably, the tumor is gastric cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, liver cancer, lung cancer, bronchial cancer, mesothelioma, kidney cancer, ovarian cancer, breast cancer, bladder cancer, uterine cancer, prostate cancer, testicular cancer, anal cancer, vaginal cancer, bile duct cancer, gallbladder cancer, head and neck cancer, spinal tumors, otolaryngology tumors, thyroid cancer, mesothelioma, bone cancer, skin cancer, melanoma, adenocarcinoma, sarcoma, neuroblastoma, glioblastoma, brain cancer, central nervous system cancer, neuroendocrine tumors, leukemia, lymphoma and myeloma.
[0463] Embodiment 45. An antibody that binds CLDN18.2, or an antigen-binding portion thereof, comprising a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 63, 69, 62, 64, 65, 66 or 70, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 68 or 72.
[0464] Embodiment 46. The antibody, or antigen-binding portion thereof, of Embodiment 45, comprising:
[0465] (1) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0466] (2) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72;
[0467] (3) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:62, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0468] (4) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0469] (5) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68;
[0470] (6) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68; or
[0471] (7) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:72.
[0472] Embodiment 47. The antibody, or antigen binding portion thereof, of Embodiment 45 or 46, comprising:
[0473] (1) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:63, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0474] (2) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:72;
[0475] (3) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:62, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0476] (4) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:64, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0477] (5) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:65, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68;
[0478] (6) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 66, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 68; or
[0479] (7) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:72.
[0480] Embodiment 48. An antibody drug conjugate comprising the antibody or antigen binding portion thereof according to any one of Embodiments 45-47.
[0481] Embodiment 49. An anti-CLDN18.2 chimeric antigen receptor comprising the antibody or antigen binding portion thereof according to any one of Embodiments 45-47.
[0482] Embodiment 50. An engineered immune effector cell comprising the anti-CLDN18.2 chimeric antigen receptor according to embodiment 49.
[0483] For the sake of clarity, the present disclosure is further illustrated with examples, but the examples do not limit the scope of the present disclosure. The reagents used in the present disclosure are generally commercially available and can be used without further purification.
[0484] Example 1: Production of anti-CLDN18.2 hybridoma monoclonal antibodies
[0485] 1. Construction of stable cell lines
[0486] The cDNA encoding human CLDN18.2 (SEQ ID NO: 41) was obtained by gene synthesis and then subcloned into the expression vector pcDNA3.1. According to the instructions of Lipofectamine 2000 transfection reagent (Thermo, catalog number 11668019), the expression vector was transfected into U2OS cells and NIH-3T3 cells, respectively, to obtain stable cell lines U2OS-CLDN18.2 and NIH-3T3-CLDN18.2.
[0487] The cDNA encoding human CLDN18.1 (SEQ ID NO: 42) was obtained by gene synthesis and then subcloned into the expression vector pcDNA3.1. According to the instructions of Lipofectamine 2000 transfection reagent (Thermo, catalog number 11668019), the expression vector was transfected into U2OS cells and NIH-3T3 cells, respectively, to obtain stable cell lines U2OS-CLDN18.1 and NIH-3T3-CLDN18.1.
[0488] 2. Mouse immunization
[0489] BALB / c mice were immunized with NIH-3T3-CLDN18.2 cells as the immunogen. Each mouse was intraperitoneally injected with 5×10 6 ~10×10 6 NIH-3T3-CLDN18.2 cells were injected intraperitoneally into each mouse 3 days before fusion. 7 NIH-3T3-CLDN18.2 cells were used for sprint immunization. After immunization, the serum of each mouse was collected for anti-CLDN18.2 specific antibody titer detection. Mice with higher antibody titers were selected for subsequent spleen cell fusion.
[0490] 3. Cell fusion
[0491] The splenocytes (1×10 8 ) and SP2 / 0 myeloma cells (5×10 7 After fusion, the cells were resuspended in HAT complete medium, distributed into 96-well plates at 0.2 mL / well, and incubated at 37°C with 5% CO 2 The cells were cultured in an incubator and after 7-10 days, the hybridoma cell culture supernatant was taken for detection.
[0492] 4. Screening of hybridomas
[0493] The binding activity of the antibody to CLDN18.2 was detected by ELISA. U2OS-CLDN18.2 cells were distributed into 96-well plates at 10,000 cells / well and incubated at 37°C with 5% CO 2 Incubate overnight in an incubator. Discard the cell culture supernatant, wash the 96-well plate 3 times with PBS buffer, and add 2% paraformaldehyde to fix at room temperature for 30 minutes. Wash the 96-well plate 3 times with PBS buffer, add 100 μL of hybridoma cell culture supernatant to each well, and incubate at room temperature for 1 hour. Wash the 96-well plate 3 times with PBS buffer, add 100 μL of HRP-Goat Anti-Mouse IgG Fcγ (Jackson immunoresearch, catalog number 115-035-071) to each well, and incubate at room temperature for 1 hour. Wash the 96-well plate 3 times with PBS buffer, add 100 μL of TMB (Thermo, catalog number 00-4201-56) to each well, incubate for 10 minutes, and then add 50 μL of stop solution (1M H 2 SO 4 ) to stop the reaction. The OD value was read at a wavelength of 450 nm using a microplate reader (Thermo, Varioskan Flash).
[0494] Hybridoma cells that are positive in ELISA detection are selected, and the binding activity of the antibodies in the culture supernatant of the hybridoma cells to the cell lines KATOIII and NUGC-4 that naturally express CLDN18.2 is detected by FACS method (for the method, see Example 3).
[0495] Example 2: Generation of anti-CLDN18.2 chimeric antibodies
[0496] 1. Obtaining cDNA
[0497] Hybridoma cells (28G3, 40F6, 22F12, 34G6 and 10D8) that were positive by ELISA and FACS were selected, and total RNA was isolated from the cells using a total RNA extraction kit (Takara, catalog number 9767) as a template, and the first-chain cDNA was synthesized using superscript III reverse transcriptase according to the instructions of the kit (Thermo, catalog number 18080051). The first-chain cDNA was used as a template, and then the heavy chain variable region and light chain variable region sequences of the antibody were amplified by PCR reaction using mouse IgG primers and Kappa primers. The PCR mixture was separated by electrophoresis in a 1% agarose / Tris-borate gel containing 0.5 μg / mL ethidium bromide. DNA fragments of the expected size were cut from the gel and purified. The purified PCR product was cloned into the pMD-19T vector (Takara, catalog number 6013), and transferred into DH5α competent E. coli cells (Takara, catalog number 9057) and cultured on LB solid culture plates. Single colonies were picked from the LB solid culture plates for DNA sequencing. The heavy chain variable region sequences and light chain variable region sequences of the antibodies (murine antibodies 28G3, 40F6, 22F12, 34G6 and 10D8) were obtained.
[0498] 2. Construction and expression of chimeric antibodies
[0499] Knocking out the fucose expression-related gene FUT8 can enhance the interaction between IgG1 and FcgRIIIa, thereby enhancing the ADCC activity of the antibody (Shields et al., 2002; Yamane-Ohnuki et al., 2004). In this example, CHO-S cells with FUT8 knockout (named CHO-S Fut8 - / - Defucosylated antibodies were prepared by
[0500] The mouse VL region gene fragment was connected to the human κ chain constant region to construct a chimeric light chain, and the mouse VH region gene fragment was connected to the human IgG1 constant region to construct a chimeric heavy chain. The chimeric heavy chain expression plasmid and the chimeric light chain expression plasmid corresponding to each antibody were co-transfected into CHO-S Fut8 - / - Protein expression was performed in cells. The transfected cells were incubated at 37°C with 8% CO 2The cells were cultured under the following conditions. After 7-10 days of culture, the cell culture supernatant was obtained by centrifugation, and the chimeric antibody in the cell culture supernatant was purified using a Protein A column (GE healthcare). The human κ light chain constant region has the amino acid sequence shown in SEQ ID NO: 44, and the human IgG1 constant region has the amino acid sequence shown in SEQ ID NO: 43. The VH / VL amino acid sequences and full-length amino acid sequences of each chimeric antibody are shown in Table 1.
[0501] Table 1. Chimeric antibody VH / VL and full-length amino acid sequences (SEQ ID NO:
[0502] Clone number VH V L Heavy chain Light chain x22F12 7 8 49 50 xi28G3 15 16 51 52 xi40F6 23 24 53 54 xi34G6 31 32 55 56 xi10D8 39 40 57 58
[0503] Example 3: Determination of Anti-CLDN18.2 Antibody Binding Activity
[0504] Based on the FACS method, the binding activity of anti-CLDN18.2 antibodies to the cell line U2OS-CLDN18.2 overexpressing CLDN18.2, the cell line KATOIII (Chinese Academy of Sciences Cell Bank) and NUGC-4 (Chinese Academy of Sciences Cell Bank) naturally expressing CLDN18.2 was analyzed. IMAB362 (prepared in-house, the heavy chain and light chain amino acid sequences are shown in SEQ ID NOs: 45 and 46 of the present application) was used as a positive control, and the IgG1 isotype control antibody (also represented as IgG1 in the examples of the present application, prepared in-house, the heavy chain and light chain amino acid sequences are shown in SEQ ID NOs: 47 and 48 of the present application) was used as a negative control.
[0505] The cell concentration was adjusted with PBS and the cells (U2OS-CLDN18.2, KATOIII or NUGC-4 cells) were plated at 3×10 5Each well was distributed into a 96-well culture plate, and then different concentrations of the test antibody were added into each well of the 96-well culture plate and incubated at 4°C for 60 minutes. For KATOIII and NUGC-4 cells: the final concentrations of xi40F6 and xi34G6 antibodies were 300nM, 100nM, 33.33nM, 11.11nM, 3.7nM, 1.23nM, 0.41nM and 0.14nM; the final concentrations of xi10D8, xi22F12 and xi28G3 antibodies were 300nM, 60nM, 12nM, 2.4nM, 0.48nM, 0.096nM, 0.0192nM and 0.00384nM; for U2OS-CLDN18.2 cells: the final concentrations of the antibodies to be tested were 150nM, 50nM, 16.67nM, 5.56nM, 1.85nM, 0.62nM, 0.21nM and 0.07nM. The supernatant was discarded, the cells were washed 3 times with pre-cooled PBS buffer, 100 μL of PE-Goat Anti-Human IgG Fcγ (Jackson immunoresearch, catalog number 109-116-170) diluted 1:200 was added to each well, and incubated at 4°C for 30 minutes. The cells were washed 3 times with pre-cooled PBS buffer, resuspended with 100 μL PBS buffer, and then the fluorescence signal was detected using a flow cytometer (Sartorius, iQUE3). The binding ability of anti-CLDN18.2 antibody to CLDN18.2 was measured by the mean fluorescence intensity (MFI) of staining.
[0506] The binding activity of anti-CLDN18.2 chimeric antibody to U2OS-CLDN18.2, KATOIII and NUGC-4 cells is shown in Figures 1A-1I As shown, combined with EC 50 The data are shown in Table 2-1, Table 2-2 and Table 2-3. The binding activities of xi28G3, xi40F6, xi22F12 and xi34G6 on three different cells are better than that of IMAB362, and the binding activity of xi10D8 is comparable to that of IMAB362.
[0507] Table 2-1. ECs bound by anti-CLDN18.2 chimeric antibodies at the cellular level 50
[0508]
[0509] Table 2-2. ECs bound by anti-CLDN18.2 chimeric antibodies at the cellular level 50
[0510]
[0511] Table 2-3. ECs bound by anti-CLDN18.2 chimeric antibodies at the cellular level 50
[0512]
[0513] Example 4: Non-specific binding of anti-CLDN18.2 antibodies
[0514] The binding activity of anti-CLDN18.2 antibody to the cell line U2OS-CLDN18.1 overexpressing CLDN18.1 (SEQ ID NO: 42) was analyzed based on the FACS method. The cell concentration was adjusted with PBS and U2OS-CLDN18.1 cells were plated at 3×10 5 Each well was added to a 96-well culture plate, and then the antibody to be tested was added to each well of the 96-well culture plate to a final concentration of 200 nM, and incubated at 4°C for 60 minutes. The supernatant was discarded, the cells were washed 3 times with pre-cooled PBS buffer, 100 μL of PE-Goat Anti-Human IgG Fcγ (Jackson immunoresearch, catalog number 109-116-170) diluted 1:200 was added to each well, and incubated at 4°C for 30 minutes. The cells were washed 3 times with pre-cooled PBS buffer, resuspended with 100 μL PBS buffer, and then the fluorescence signal was detected using a flow cytometer (Sartorius, iQUE3). The nonspecific binding of anti-CLDN18.2 antibodies to U2OS-CLDN18.1 cells was measured by the mean fluorescence intensity (MFI) of staining, and the IgG1 isotype control antibody (prepared in-house, the heavy chain and light chain amino acid sequences are shown in SEQ ID NOs: 47 and 48 of the present application) was used as a control. The 2 times of the IgG1 isotype control antibody was used as a benchmark to determine whether nonspecific binding existed.
[0515] The results are shown in Table 3. The MFI values of the anti-CLDN18.2 chimeric antibody and the control group IgG1 isotype control antibody were similar, indicating that the anti-CLDN18.2 chimeric antibody had no non-specific binding to U2OS-CLDN18.1 cells.
[0516] Table 3. Non-specific binding of anti-CLDN18.2 chimeric antibodies to U2OS-CLDN18.1 cells
[0517] Antibody MFI xi10D8 8031 x22F12 8943 xi28G3 7556 xi40F6 7071 xi34G6 7633 IMAB362 6221 IgG1 6035
[0518] Example 5: Construction, expression and purification of anti-CLDN18.2 humanized antibodies
[0519] The anti-CLDN18.2 chimeric antibodies xi22F12 and xi28G3 were humanized, respectively. Five humanized antibodies were obtained after humanization of the chimeric antibody xi22F12, which were named hu22F12-1.1, hu22F12-1.2, hu22F12-1.3, hu22F12-1.4 and hu22F12-1.5, respectively; two humanized antibodies were obtained after humanization of the chimeric antibody xi28G3, which were named hu28G3-1.2 and hu28G3-1.5, respectively. The amino acid sequence and nucleotide sequence of the heavy chain and light chain of each humanized antibody are shown in Table 4.
[0520] Table 4. Sequence information of humanized antibodies (SEQ ID NO:)
[0521]
[0522]
[0523] The nucleotide sequences encoding the above humanized antibodies were synthesized and cloned into the pcDNA3.1(+) expression vector. Each antibody was expressed using the Expi293 expression kit (Thermo Fisher, catalog number A14635). The constructed expression vector containing the above nucleotide sequence was first transfected into Expi293F cells and then incubated at 37°C and 8% CO on an orbital shaker platform rotating at 130 rpm. 2 The cells were cultured in an incubator with a humidified atmosphere of . The culture supernatant was collected and protein was purified using protein A magnetic beads (Genscript, catalog number L00273). The protein concentration was measured by UV-Vis spectrophotometer (NanoDroplite, Thermo Scientific).
[0524] Example 6: Binding activity determination of anti-CLDN18.2 humanized antibodies
[0525] The binding of each anti-CLDN18.2 humanized antibody prepared in Example 5 to KATOIII cells (source: Cell Resource Center, Institute of Basic Medicine, Chinese Academy of Medical Sciences) and NUGC-4 cells (source: Kebai Bio) that naturally express CLDN18.2, as well as the BxPC-3CLDN18.2 cell line overexpressing CLDN18.2 (source: Kangyuan Bochuang, catalog number KC-1272) was analyzed by flow cytometry. The negative control was hIgG1 monoclonal antibody (Bio-Int, catalog number B117901).
[0526] Take KATOIII, NUGC-4 and BxPC-3CLDN18.2 in the logarithmic growth phase and adjust the cell density to 1×10 using Running buffer (MACS, Cat. No. 130-091-221). 6 ~2×10 6 / mL, 50μL per well was inoculated in a 96-well U-shaped cell culture plate (Costar, Catalog No.: 3799). Different concentrations of anti-CLDN18.2 humanized antibody were prepared using Running buffer, with the highest antibody concentration being 500nM, 5-fold dilution, and a total of 8 concentration gradients. Different concentrations of antibodies were added to the above 96-well cell culture plate, 50μL per well, mixed and incubated at 4°C for 1 hour. After adding pre-cooled Running buffer to wash the cells, the supernatant was discarded, and pre-cooled PE-conjugated goat anti-human IgG Fcγ antibody (Jackson Immuno Research, Catalog No. 109-116-170) was added, 100μL per well was resuspended, mixed and incubated at 4°C for 30 minutes. After washing, 50μL / well of pre-cooled Running buffer was added to resuspend the cells, mixed and flow acquisition was performed on a flow cytometer (Sartorius, Model iQue 3), and data analysis was performed using software.
[0527] The binding activity of anti-CLDN18.2 humanized antibodies to KATOIII, NUGC-4 and BxPC-3CLDN18.2 is shown in Tables 5-1, 5-2 and Figures 2A-2D shown.
[0528] Table 5-1. EC binding of anti-CLDN18.2 humanized antibodies to tumor cells 50 and the maximum combined value
[0529]
[0530] Table 5-2. Binding EC of anti-CLDN18.2 humanized antibodies to tumor cells 50 and the maximum combined value
[0531]
[0532] Example 7: Construction, expression and purification of anti-CLDN18.2 / anti-CD3 bispecific antibodies
[0533] according to Figure 3The anti-CLDN18.2 / anti-CD3 bispecific antibodies were constructed in the configuration shown and named CNC39-L6 and CNC41-L6, respectively, wherein the first antigen binding moiety is a Fab that binds to CLDN18.2, and the second antigen binding moiety is a scFv that binds to CD3. Specifically, both CNC39-L6 and CNC41-L6 have three polypeptide chains, and their amino acid sequences and nucleotide sequences are shown in Table 6.
[0534] The nucleotide sequences encoding anti-CLDN18.2-HC, anti-CLDN18.2-LC and anti-CD3-scFv-Fc were synthesized and cloned into the pcDNA3.1(+) expression vector. The above-constructed expression vectors were co-transfected into ExpiCHO using the ExpiCHO transfection kit (Thermo Fisher, catalog number A29133) at a ratio of vector anti-CLDN18.2-HC: vector anti-CLDN18.2-LC: vector anti-CD3-scFv-Fc = 1:1.5:1.5, and the transfection density was 6×10 6 Cells were cultured continuously until the 10th to 15th day after transfection and the cell culture supernatant was collected by centrifugation. Protein purification system (GE Healthcare) was used for protein A affinity chromatography, ion exchange chromatography and gel chromatography. The protein concentration was measured by UV-Vis spectrophotometer (NanoDrop lite, Thermo Scientific). The above-mentioned bispecific antibody with the expected structure and sequence was confirmed by electrophoresis (reducing SDS-PAGE), molecular weight (Orbitrap MS) and sequence detection analysis.
[0535] The anti-CLDN18.2 / anti-CD3 bispecific antibody AMG910 (Amgen) was constructed as a reference (Benchmark, BM). Specifically, AMG910 has one polypeptide chain, and the amino acid sequence is shown in Table 6. The nucleotide sequence encoding the AMG910 polypeptide chain was synthesized and cloned into the pcDNA3.1(+) expression vector. The expression vector of AMG910 was transfected into ExpiCHO using the ExpiCHO transfection kit (Thermo Fisher, A29133), and the transfection density was 6×10 6 The cells were cultured continuously until the 10th to 15th day after transfection, and the cell culture supernatant was collected by centrifugation. Protein purification was performed using a protein purification system (GE Healthcare) by protein A affinity chromatography, CHT chromatography, and gel chromatography.
[0536] Table 6. Sequence information of anti-CLDN18.2 / anti-CD3 bispecific antibodies
[0537]
[0538] “-” means not applicable.
[0539] Example 8: Binding activity determination of anti-CLDN18.2 / anti-CD3 bispecific antibodies
[0540] Surface plasmon resonance technology was used to detect the binding of anti-CLDN18.2 / anti-CD3 bispecific antibody to human CLDN18.2 protein (KACTUS, catalog number CLD-HE1822B) and human CD3ε protein (Acro, catalog number CDE-H5223).
[0541] The affinity of the antibody to CLDN18.2 was tested using a biomolecular interaction analysis system (GE, Biacore 8K). Amino-coupled avidin (Thermo Scientific TM , catalog number 31000) to a CM5 sensor chip using running buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 12H 2 O, 1.8 mM KH 2 PO 4 , 0.05% surfactant P-20 (w / v), pH 7.4) 5-fold dilution of CLDN18.2 protein, 5 μL / min flow rate through the experimental channel for capture. Use running buffer to dilute each antibody to 100nM, 50nM, 25nM, 12.5nM, 6.25nM and 3.125nM, 50μL / min flow rate for binding, the binding time is set to 200s, then stop the injection for dissociation, and the dissociation time is set to 400s. Software Biacore 8K Control Software 3.0 real-time acquisition of data signals, software Biacore Insight Evaluation Software 3.0 data analysis, Langmuir 1:1 model fitting, calculation of binding rate constant k a (1 / Ms), dissociation rate constant k d (1 / s), equilibrium dissociation constant K D (M) value.
[0542] The affinity of the antibody to CD3ε was tested using a biomolecular interaction analysis system (GE, Biacore 8K). Amino-coupled Anti-hIgG (Fc) antibody (GE, catalog No. BR-1008-39) was attached to a CM5 sensor chip and run in a running buffer (437 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 12H 2 O, 1.8 mM KH 2 PO 4 , 0.05% surfactant P-20 (w / v), pH 7.4) was used to dilute the antibody to 2 μg / mL, and the flow rate was 30 μL / min for capture through the experimental channel. CD3ε was diluted to 100nM, 50nM, 25nM, 12.5nM, 6.25nM and 3.125nM using running buffer, and the flow rate was 50μL / min for binding. The binding time was set to 200s, after which the injection was stopped for dissociation, and the dissociation time was set to 600s. The software Biacore 8K Control Software 3.0 collected data signals in real time, and the software Biacore Insight Evaluation Software 3.0 analyzed the data. The Langmuir 1:1 model was used for fitting and the binding rate constant k was calculated. a (1 / Ms), dissociation rate constant k d (1 / s), equilibrium dissociation constant K D (M) value.
[0543] The affinities of CNC39-L6 and CNC41-L6 to human CLDN18.2 protein are shown in Table 7-1, and the affinities to human CD3ε protein are shown in Table 7-2.
[0544] Table 7-1. Affinity of anti-CLDN18.2 / anti-CD3 bispecific antibodies to human CLDN18.2 protein
[0545] Antibody <![CDATA[k a (1 / Ms)]]> <![CDATA[k d (1 / s)]]> <![CDATA[K D (M)]]> CNC39-L6 2.34E+05 7.95E-04 3.39E-09 CNC41-L6 2.90E+05 2.04E-03 7.02E-09
[0546] Table 7-2. Affinity of anti-CLDN18.2 / anti-CD3 bispecific antibodies to human CD3ε protein
[0547]
[0548]
[0549] Example 9: Binding of anti-CLDN18.2 / anti-CD3 bispecific antibodies to tumor cells expressing CLDN18.2
[0550] The binding of anti-CLDN18.2 / anti-CD3 bispecific antibodies (including AMG910, CNC39-L6 and CNC41-L6) to KATOIII cells (source: Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences) and NUGC-4 cells (source: Kebai Bio) that naturally express CLDN18.2, as well as the BxPC-3CLDN18.2 cell line overexpressing CLDN18.2 (source: Kangyuan Bochuang, catalog number KC-1272) were analyzed by flow cytometry. The negative control was hIgG1 monoclonal antibody (Bio-Int, catalog number B117901).
[0551] KATOIII cells, NUGC-4 cells and BxPC-3CLDN18.2 cells in the logarithmic growth phase were taken and the cell density was adjusted to 1×10 using Running buffer (MACS, Cat. No. 130-091-221). 6 ~2×10 6 / mL, 50μL per well was inoculated in a 96-well U-shaped cell culture plate (Costar, Catalog No.: 3799). Different concentrations of anti-CLDN18.2 / anti-CD3 bispecific antibodies were prepared using Running buffer, with the highest antibody concentration being 500nM, and 4-fold dilutions, with a total of 8 concentration gradients. Different concentrations of antibodies were added to the above 96-well cell culture plate, 50μL per well, mixed and incubated at 4°C for 1 hour. After adding pre-cooled Running buffer to wash the cells, the supernatant was discarded, and pre-cooled PE-conjugated goat anti-human IgG Fcγ antibody (JacksonImmuno Research, Catalog No. 109-116-170) was added, 100μL per well was resuspended, mixed and incubated at 4°C for 30 minutes. After washing, 50μL / well of pre-cooled Running buffer was added to resuspend the cells, mixed and flow acquisition was performed on a flow cytometer (Sartorius, Model iQue 3), and data analysis was performed using software.
[0552] Table 8 and Figures 4A-4C The binding ability of anti-CLDN18.2 / anti-CD3 bispecific antibodies to KATOIII, NUGC-4 and BxPC-3CLDN18.2 was shown. The results showed that the binding activity of CNC39-L6 to KATOIII and NUGC-4 was stronger than that of CNC41-L6 and the reference substance AMG910; the binding activity of CNC39-L6 to BxPC-3CLDN18.2 was comparable to that of CNC41-L6, and both were stronger than the reference substance AMG910.
[0553] Table 8. Binding EC values of anti-CLDN18.2 / anti-CD3 bispecific antibodies to tumor cells expressing CLDN18.2 50 and the maximum combined value
[0554]
[0555] Example 10: Killing of tumor cells by anti-CLDN18.2 / anti-CD3 bispecific antibodies
[0556] Human PBMC (peripheral blood mononuclear cells) were used to provide T cells to study the killing effect of anti-CLDN18.2 / anti-CD3 bispecific antibodies (including: AMG910, CNC39-L6 and CNC41-L6) on KATOIII cells (Source: Cell Resource Center, Institute of Basic Medicine, Chinese Academy of Medical Sciences) and NUGC-4 cells (Source: Kebai Bio) that naturally express CLDN18.2, as well as BxPC-3CLDN18.2 cell lines that overexpress CLDN18.2 (Source: Kangyuan Bochuang, catalog number KC-1272). The negative control was hIgG1 monoclonal antibody (Baiying Bio, catalog number B117901).
[0557] The target cells KATOIII, NUGC-4 and BxPC-3CLDN18.2 were cultured in RPMI-1640 medium (Biochannel, Catalog No. BC-M-017) containing 2% (v / v) FBS (Gibco, Catalog No. 10099-141C) to adjust the cell density to 5×10 5 / mL, 50μL per well was inoculated in a 96-well cell culture plate (Costar, Cat. No. 3599). Different concentrations of anti-CLDN18.2 / anti-CD3 bispecific antibodies were prepared using RPMI-1640 medium containing 2% (v / v) FBS: for KATOIII and NUGC-4 cells, the maximum concentration of CNC39-L6 and CNC41-L6 was 5nM; for BxPC-3CLDN18.2, the maximum concentrations of CNC39-L6 and CNC41-L6 were 0.3125nM, and the maximum concentration of AMG910 was 1.25nM; 4-fold dilution, a total of 9 concentration gradients. Different concentrations of antibodies were added to the above 96-well cell culture plate, 50μL per well. Effector cells Human PBMCs were adjusted to a cell density of 2.5×10 using RPMI-1640 medium containing 2% (v / v) FBS. 6 / mL, 100μL per well. Set up the dosing group (target cell 50μL + effector cell 100μL + antibody 50μL), target cell group (target cell 50μL + culture medium 150μL), effector cell group (human PBMC 100μL + culture medium 100μL), target cell + effector cell group (target cell 50μL + effector cell 100μL + culture medium 50μL), blank control group (culture medium 200μL), lysate control group (culture medium 200μL + lysate 20μL), and target cell maximum release group (target cell 50μL + culture medium 150μL + lysate 20μL), the effector-target ratio was 10:1, and the cells were incubated for 21 hours. The lysate (Promega, catalog number G182A) in the target cell maximum release group and the lysate control group was added 45min before detection. Use The cells were tested using a non-radioactive cytotoxicity detection kit (Promega, G1780). Finally, the absorbance at a wavelength of 490 nm was measured in an ELISA reader to calculate the cell lysis rate.
[0558]
[0559] Figures 5A-5C Table 9 shows the cleavage rate of anti-CLDN18.2 / anti-CD3 bispecific antibodies against KATOIII, NUGC-4 and BxPC-3CLDN18.2. The results showed that the killing activity of bispecific antibodies CNC39-L6 and CNC41-L6 against target cells KATOIII, NUGC-4 and BXPC3-18.2 was stronger than that of the reference substance AMG910.
[0560] Table 9. EC of each antibody for lysis of NCI-H929 cells 50 Value and maximum lysis rate
[0561]
[0562] Example 11: Activation of T cells by anti-CLDN18.2 / anti-CD3 bispecific antibodies
[0563] By detecting the expression of T cell activation markers CD69 and CD25, the activation of T cells by anti-CLDN18.2 / anti-CD3 bispecific antibodies (including: AMG910, CNC39-L6 and CNC41-L6) in the presence of target cells expressing CLDN18.2 was studied, and the ability to activate T cells was determined by the degree of concentration-dependent upregulation of the markers. The negative control was hIgG1 monoclonal antibody (Bio-Ying Bio, catalog number B117901).
[0564] The target cell KATOIII was cultured in RPMI-1640 medium (Biochannel, Catalog No. BC-M-017) containing 2% (v / v) FBS (Gibco, Catalog No. 10099-141C) to adjust the cell density to 5×10 5 / mL, 50μL per well was inoculated in a 96-well cell culture plate (Costar, Cat. No.: 3599). Different concentrations of anti-CLDN18.2 / anti-CD3 bispecific antibodies were prepared using RPMI-1640 medium containing 2% (v / v) FBS. The highest antibody concentration was 1.25-5nM, with 4-fold dilutions and a total of 8 concentration gradients. Different concentrations of antibodies were added to the above 96-well cell culture plate, 50μL per well. Effector cells Human PBMCs were adjusted to a cell density of 2.5×10 using RPMI-1640 medium containing 2% (v / v) FBS. 6 / mL, 100μL per well. Set up the drug administration group (target cell 50μL + effector cell 100μL + antibody 50μL), target cell group (target cell 50μL + culture medium 150μL), effector cell group (human PBMC 100μL + culture medium 100μL), target cell + effector cell group (target cell 50μL + effector cell 100μL + culture medium 50μL), blank control group (culture medium 200μL), lysate control group (culture medium 200μL + lysate 20μL), and target cell maximum release group (target cell 50μL + culture medium 150μL + lysate 20μL), the effector-target ratio was 10:1, and the cells were incubated for 21 hours. The supernatant was removed by centrifugation, and the cells were washed by centrifugation with pre-cooled Running buffer (MACS, Catalog No. 130-091-221). After removing the supernatant, 100 μL Running buffer was added to each well, and the cells were mixed. 2.5 μL of CD4-PE (BD, Catalog No. 555347), CD8-APC-Cy7 (BD, Catalog No. 557834), 10 μL of CD25-BV421 (BD, Catalog No. 562442), and CD69-FITC (BD, Catalog No. 555530) were added to each well, and incubated on ice for 30 minutes. The cells were washed with pre-cooled Running buffer, and 200 μL / well Running buffer was added to resuspend the cells. After mixing, the cells were placed in a multi-channel flow cytometer (Thermo, Model: Attnue NxT) for detection.
[0565] Figures 6A-6D Table 10 shows the activation degree of T cells in the presence of target cells KATOIII; wherein CD25 / CD4 indicates CD25 + CD4 + The ratio of cell number, CD69 / CD4 indicates CD69 +CD4 + The ratio of cell number, CD25 / CD8 indicates CD25 + CD8 + The ratio of cell numbers, CD69 / CD8, indicates CD69 + The number of cells accounted for CD8 + The expression of CD25 and CD69 increased significantly, indicating that T cells were activated. The results showed that the bispecific antibodies CNC39-L6 and CNC41-L6 could effectively activate T cells in the presence of target cells KATOIII.
[0566] Table 10. EC of T cell activation by anti-CLDN18.2 / anti-CD3 bispecific antibodies in the presence of KATOIII 50
[0567]
[0568] The sequence information of the present disclosure is summarized in Table S2 below.
[0569] Table S2. Sequence information
[0570]
[0571]
[0572]
[0573]
[0574]
[0575]
[0576]
[0577]
[0578]
[0579]
[0580]
[0581] All patents, patent applications and other identified publications are expressly incorporated herein by reference for the purposes of description and disclosure. These publications are provided solely because their disclosure predates the filing date of the present disclosure. All statements regarding the dates of these documents or representations of the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any reference to these publications herein does not constitute an admission that the publications become part of the common general knowledge in the art in any country.
[0582] Although the present disclosure has been described in detail above with general descriptions and specific implementation schemes, it is obvious to those skilled in the art that some modifications or improvements can be made to the present disclosure. Therefore, these modifications or improvements made without departing from the spirit of the present disclosure are within the scope of protection claimed by the present disclosure.
Claims
1. A bispecific antibody comprising a first antigen-binding portion that binds CLDN18.2 and a second antigen-binding portion that binds CD3, wherein: The first antigen binding portion comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, 9, 17, 25 or 33, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 59, 10, 18, 26 or 34, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 3, 11, 19, 27 or 35, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 4, 12, 20, 28 or 36, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, 13, 21, 29 or 37, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 6, 14, 22, 30 or 38.
2. The bispecific antibody according to claim 1, wherein The first antigen binding moiety comprises: (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; wherein X1 is selected from N or Q, and X2 is selected from S or T; (2) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; (3) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 60, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; (4) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:61, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6; (5) a HCDR1 comprising the amino acid sequence of SEQ ID NO:9, a HCDR2 comprising the amino acid sequence of SEQ ID NO:10, a HCDR3 comprising the amino acid sequence of SEQ ID NO:11, a LCDR1 comprising the amino acid sequence of SEQ ID NO:12, a LCDR2 comprising the amino acid sequence of SEQ ID NO:13, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:14; (6) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22; (7) a HCDR1 comprising the amino acid sequence of SEQ ID NO:25, a HCDR2 comprising the amino acid sequence of SEQ ID NO:26, a HCDR3 comprising the amino acid sequence of SEQ ID NO:27, a LCDR1 comprising the amino acid sequence of SEQ ID NO:28, a LCDR2 comprising the amino acid sequence of SEQ ID NO:29, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:30; or (8) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:36, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:37, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:
38.
3. A bispecific antibody comprising a first antigen binding portion that binds CLDN18.2 and a second antigen binding portion that binds CD3, wherein: The first antigen binding portion comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:7, 15, 23, 31, 39, 67 or 71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:8, 16, 24, 32, 40, 68 or 72.
4. The bispecific antibody according to claim 3, wherein The first antigen binding moiety comprises: (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:8; (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 15, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 16; (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:24; (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:31, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:32; (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40; (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:62, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68; (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68; (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68; (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:68; (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:68; (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:67, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:68, wherein X3 is selected from I or L, X4 is selected from N or Q, X5 is selected from S or T, X6 is selected from V or L, X7 is selected from T or S, X8 is selected from V or K, and X9 is selected from T or N; (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:69, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:72; (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence of SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence of SEQ ID NO:72; or (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 71, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 72, wherein X 10 Selected from V or I, X 11 Select from A or T, X 12 Select from Q or K, X 13 Select from T or R, X 14 Select from S or N.
5. The bispecific antibody according to any one of claims 1 to 4, wherein The first antigen binding portion comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:7, 15, 23, 31, 39, 62, 63, 64, 65, 66, 67, 69, 70 or 71, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8, 16, 24, 32, 40, 68 or 72.
6. The bispecific antibody according to any one of claims 1 to 5, wherein The first antigen binding moiety comprises: (1) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8; (2) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:15, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:16; (3) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24; (4) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:31, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:32; (5) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40; (6) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:62, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68; (7) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68; (8) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68; (9) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68; (10) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68; (11) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68; (12) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72; (13) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:72; or (14) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:71, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:
72.
7. The bispecific antibody according to any one of claims 1 to 6, wherein The first antigen binding moiety comprises: (1) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8; (2) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16; (3) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:23, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:24; (4) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:31, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:32; (5) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:40; (6) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:62, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68; (7) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:63, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68; (8) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:64, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68; (9) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:65, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68; (10) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:66, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68; (11) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:67, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:68; (12) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:72; (13) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 70, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 72; or (14) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:71, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:
72.
8. The bispecific antibody according to claim 1, wherein The first antigen binding portion comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:
6.
9. The bispecific antibody according to claim 8, wherein The first antigen binding portion comprises: a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:68; preferably, the first antigen binding portion comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:
68.
10. The bispecific antibody according to claim 1, wherein The first antigen binding portion comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:9, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:10, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:11, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:14.
